[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 434
1. Nikgoo A, Mirafshariyeh SA, Kazeminajad B, Eshkevari PS, Fatemitabar SA: Burkitt's Lymphoma of maxillary sinuses: review of literature and report of bilateral case. J Oral Maxillofac Surg; 2009 Aug;67(8):1755-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's Lymphoma of maxillary sinuses: review of literature and report of bilateral case.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Maxillary Sinus Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / analysis. Biopsy. Humans. Male. Neprilysin / analysis. Palatal Neoplasms / diagnosis. Radiography, Panoramic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615595.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 38
  •  go-up   go-down


2. Wakabi W: Kenya and Uganda grapple with Burkitt lymphoma. Lancet Oncol; 2008 Apr;9(4):319
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kenya and Uganda grapple with Burkitt lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology. Disease Outbreaks
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Developing Countries. Female. Humans. Incidence. Kenya / epidemiology. Male. Severity of Illness Index. Sex Distribution. Survival Analysis. Uganda / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2008 Jun;9(6):512-3 [18510986.001]
  • (PMID = 18380064.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  •  go-up   go-down


3. Chishima F, Hayakawa S, Ohta Y, Sugita K, Yamazaki T, Sugitani M, Yamamoto T: Ovarian Burkitt's lymphoma diagnosed by a combination of clinical features, morphology, immunophenotype, and molecular findings and successfully managed with surgery and chemotherapy. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:337-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian Burkitt's lymphoma diagnosed by a combination of clinical features, morphology, immunophenotype, and molecular findings and successfully managed with surgery and chemotherapy.
  • Ovarian involvement as an initial manifestation of lymphoma, without detectable extraovarian disease, is a rare occurrence.
  • The diagnosis of ovarian lymphoma is almost invariably unsuspected until the tumor has been examined histologically.
  • Presence of abnormal lymphoid cells in pleural effusion led to presurgical assumption that the pelvic mass noted on computerized tomography examination might be an ovarian lymphoma.
  • Clinical, histologic, and molecular examination revealed Burkitt's lymphoma of the ovary with c-myc gene rearrangement and mRNA expression of multiple cytokines.
  • Immunophenotype and molecular findings allowed reliable discrimination of Burkitt's lymphoma from diffuse large B-cell lymphoma and other lymphomas.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Herpesvirus 4, Human / isolation & purification. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Cytokines / analysis. Doxorubicin / administration & dosage. Female. Genes, myc / genetics. Gynecologic Surgical Procedures. Humans. Prednisolone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cytokines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


Advertisement
4. Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J, GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK): Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia; 2006 Dec;20(12):2155-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study.
  • Adult patients with acute lymphoblastic leukemia (ALL) and t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4 have a poor outcome.
  • CR rates achieved by MLL and E2A groups were similar to other B-cell ALL (87, 82 and 86% respectively).
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / therapy. Hematopoietic Stem Cell Transplantation. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Basic Helix-Loop-Helix Transcription Factors / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 4 / genetics. DNA-Binding Proteins / genetics. Female. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein / genetics. Nuclear Proteins / genetics. Prospective Studies. Proto-Oncogene Proteins / genetics. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039234.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / TCF3 protein, human; 0 / pbx1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 150826-18-9 / AFF1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


5. Salaverria I, Zettl A, Beà S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Müller-Hermelink HK, Campo E, Rosenwald A, Leukemia and Lymphoma Molecular Profiling Project (LLMPP): Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica; 2008 Sep;93(9):1327-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.
  • BACKGROUND: Burkitt's lymphoma is an aggressive B-cell lymphoma characterized by typical morphological, immunophenotypic and molecular features.
  • Gene expression profiling provided a molecular signature of Burkitt's lymphoma, but also demonstrated that a subset of aggressive B-cell lymphomas not fulfilling the current World Health Organization criteria for the diagnosis of Burkitt's lymphoma nonetheless show a molecular signature of Burkitt's lymphoma ('discrepant Burkitt's lymphoma').
  • Given the different treatment of Burkitt's lymphoma and diffuse large B-cell lymphomas we investigated molecular differences within gene expression-defined Burkitt's lymphoma.
  • DESIGN AND METHODS: We studied tumors from 51 Burkitt's lymphoma patients, comprising 26 with classic Burkitt's lymphoma, 17 with atypical Burkitt's lymphoma and 8 with 'discrepant Burkitt's lymphoma', by comparative genomic hybridization and gene expression profiling.
  • RESULTS: Classic and atypical Burkitt's lymphoma (excluding 'discrepant Burkitt's lymphoma'), in adult and pediatric cases do not differ in underlying genomic imbalances or gene expression suggesting that these subgroups are molecularly homogeneous.
  • 'Discrepant Burkitt's lymphoma', however, differ dramatically in the absolute number of alterations from classic/atypical Burkitt's lymphoma and from diffuse large B-cell lymphoma.
  • Moreover, this category includes lymphomas that carry both the t(14;18) and t(8;14) translocations and are clinically characterized by presentation in adult patients and an aggressive course.
  • CONCLUSIONS: Pediatric and adult Burkitt's lymphoma are molecularly homogeneous, whereas 'discrepant Burkitt's lymphoma' differ in underlying genetic and clinical features from typical/atypical Burkitt's lymphoma.
  • 'Discrepant Burkitt's lymphoma' may therefore form a distinct genetic subgroup of aggressive B-cell lymphomas, which show poor response to multi-agent chemotherapy.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human / genetics. Comparative Genomic Hybridization. Gene Expression Regulation, Neoplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698080.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1-CA84967
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


6. Haralambieva E, Boerma EJ, van Imhoff GW, Rosati S, Schuuring E, Müller-Hermelink HK, Kluin PM, Ott G: Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol; 2005 Aug;29(8):1086-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.
  • A prompt distinction of Burkitt lymphoma (BL) versus diffuse large B cell lymphomas (DLBCL) has important clinical implications; however, this distinction can be difficult.
  • We analyzed 74 adult gray zone and 10 reference pediatric BL using immunohistochemistry (Ki-67, CD10, bcl2, bcl6) and fluorescence in situ hybridization (FISH) for MYC, BCL2, and BCL6 breakpoints.
  • In the adult group, algorithm A resulted in 21 adult BL and 52 DLBCL and algorithm B in 23 BL and 51 "non-Burkitt" lymphomas (nBL); 9 cases (12%) contained two different translocations and were categorized as nBL in algorithm B.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma / genetics. Lymphoma / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Algorithms. Biomarkers, Tumor / analysis. Child. Child, Preschool. DNA-Binding Proteins / analysis. Female. Humans. Immunohistochemistry. Immunophenotyping. Ki-67 Antigen / analysis. Male. Middle Aged. Neprilysin / analysis. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006805.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


7. de Leval L, Hasserjian RP: Diffuse large B-cell lymphomas and burkitt lymphoma. Hematol Oncol Clin North Am; 2009 Aug;23(4):791-827
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphomas and burkitt lymphoma.
  • Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children.
  • In this article, the authors summarize the recent advances pertaining to these B-cell neoplasms, following the latest World Health Organization classification and focusing on changes introduced since the previous edition.
  • These changes include the addition of variants and subgroups of DLBCLs and "borderline" categories for high-grade B-cell neoplasms that show features intermediate between DLBCL and classical Hodgkin lymphoma, or between DLBCL and BL.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / immunology. Antigens, CD5 / immunology. Child. Diagnosis, Differential. Humans. Immunophenotyping. World Health Organization

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577170.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD5
  • [Number-of-references] 162
  •  go-up   go-down


8. Morales P, Torres J, Pérez-Enguix D, Solé A, Pastor A, Segura A, Zurbano F: Lymphoproliferative disease after lung and heart-lung transplantation: first description in Spain. Transplant Proc; 2005 Nov;37(9):4059-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than 90% of posttransplantation lymphoproliferative syndromes (PTLS) are considered to be associated with Epstein-Barr virus, and 86% are of the B-cell line.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Humans. Lung / radiography. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Heart Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386626.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


9. Smith JE, Medley CD, Tang Z, Shangguan D, Lofton C, Tan W: Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem; 2007 Apr 15;79(8):3075-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aptamers were selected using a cell-based SELEX strategy in our laboratory for cancer cells that, when utilized in this method, allow for the selective recognition of the cells from complex mixtures including fetal bovine serum samples.
  • Aptamer-conjugated magnetic nanoparticles were used for the selective targeting cell extraction, and aptamer-conjugated fluorescent nanoparticles were employed for sensitive cellular detection.
  • Fluorescent imaging and a microplate reader were used for cellular detection to demonstrate the wide applicability of this methodology for medical diagnostics and cell enrichment and separation.
  • [MeSH-major] Aptamers, Nucleotide / chemistry. Burkitt Lymphoma / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, B-Cell / pathology. Nanoparticles / chemistry. SELEX Aptamer Technique / methods
  • [MeSH-minor] Cell Line, Tumor. Fluorescent Dyes / chemistry. Humans. Magnetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17348633.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / Fluorescent Dyes
  •  go-up   go-down


10. Kenkre VP, Stock W: Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S231-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma/leukemia: improving prognosis.
  • Burkitt lymphoma/leukemia (BL) has become a very curable mature B-cell neoplasm.
  • The more widespread use of highly active antiretroviral therapy in the HIV patient with BL has allowed the use of similar aggressive therapies that are used for the non-HIV BL patients, with commensurate improvements in outcomes in this high-risk population.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Gene Expression Regulation, Neoplastic. Leukemia / diagnosis. Leukemia / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Child. Clinical Trials as Topic. Gene Expression Profiling. HIV Infections / complications. HIV Infections / drug therapy. Humans. Medical Oncology. Prognosis. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778846.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 47
  •  go-up   go-down


11. Lin YS, Lin LC, Huang MH, Huang AJ, Huang YT: Down-regulation of gp130 in nasopharyngeal carcinoma. Am J Rhinol Allergy; 2009 Jan-Feb;23(1):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell lines including EBV(-), Burkitt-like lymphoma (BJAB) cells, human adult peripheral blood mononuclear cells, and lymphoblastoid cell lines were used to provide evidence of the biological function of gp130.
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Middle Aged. Protein Subunits. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379608.001).
  • [ISSN] 1945-8924
  • [Journal-full-title] American journal of rhinology & allergy
  • [ISO-abbreviation] Am J Rhinol Allergy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Protein Subunits; 0 / RNA, Neoplasm; 0 / glycoprotein 130, human
  •  go-up   go-down


12. Lazzi S, Bellan C, Amato T, Palummo N, Cardone C, D'Amuri A, De Luca F, Beyanga M, Facchetti F, Tosi P, Leoncini L: Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 infection in reactive lymphoid tissues: a model for KSHV/HHV-8-related lymphomas? Hum Pathol; 2006 Jan;37(1):23-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found the presence of KSHV/HHV-8 in 2 cases of lymph nodes partially involved by Burkitt's lymphoma and KS and in 1 case of multicentric Castleman disease.
  • Interestingly, among KSHV/HHV-8-positive cases, in those in which there was also lymphoma, the neoplastic cells were negative for KSHV/HHV-8.
  • This further confirms that KSHV/HHV-8 is involved in the neoplastic transformation of only certain types of lymphoma, probably in relation to their precursor infected cell.
  • [MeSH-major] Germinal Center / virology. Herpesvirus 8, Human / isolation & purification. Lymphoma / virology. Sarcoma, Kaposi / virology
  • [MeSH-minor] Adult. Antigens, Viral. B-Lymphocytes / pathology. B-Lymphocytes / virology. Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Cell Transformation, Neoplastic. Child. DNA, Viral / analysis. Female. Giant Lymph Node Hyperplasia / pathology. Giant Lymph Node Hyperplasia / virology. HIV / genetics. HIV / isolation & purification. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged. Nuclear Proteins. RNA, Viral / analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360412.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / DNA, Viral; 0 / Nuclear Proteins; 0 / RNA, Viral; 0 / latency-associated nuclear antigen
  •  go-up   go-down


13. Obukhova TN, Bariakh EA, Kaplanskaia IB, Domracheva EB, Kravchenko SK: [Detection of translocations diagnostic for Berkitt's lymphoma by fluorescent in situ hybridization on histological sections of paraffin blocks]. Ter Arkh; 2007;79(7):80-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of translocations diagnostic for Berkitt's lymphoma by fluorescent in situ hybridization on histological sections of paraffin blocks].
  • AIM: To test feasibility of detection of translocations which are diagnostic for Berkitt's lymphoma with the method of fluorescence in situ hibridization (FISH) on histological sections of paraffin blocks.
  • Translocation t(8;14)(q24;q32) and its variants were not detected in 22 patients, the diagnosis was changed for diffuse large B-cell lymphoma (DLBCL).
  • CONCLUSION: Typical for BL clinical, morphological and immunological picture may present in extra-nodal diffuse large B-cell lymphoma with high proliferative activity.
  • Differential diagnosis between BL and the latter lymphoma is possible only basing on detection of translocation t(8;14)(q24;q32) or its variants.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. In Situ Hybridization, Fluorescence / methods. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Microtomy. Middle Aged. Paraffin Embedding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17802797.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


14. Wetter A, Schaudt A, Lehnert T, Schmidt-Matthiesen A, Jacobi V, Vogl TJ: Small-bowel intussusception as a rare differential diagnosis in HIV-positive patients with acute abdominal pain. Eur Radiol; 2006 Apr;16(4):952-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-bowel intussusception as a rare differential diagnosis in HIV-positive patients with acute abdominal pain.
  • [MeSH-major] Abdomen, Acute. Abdominal Pain / radiography. Abdominal Pain / virology. Burkitt Lymphoma / complications. Burkitt Lymphoma / radiography. HIV Infections / complications. Intestinal Neoplasms / radiography. Intestinal Neoplasms / virology. Intestine, Small. Intussusception / radiography. Intussusception / virology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed


15. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol; 2005 Jul 1;23(19):4430-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
  • PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.
  • PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome


16. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood; 2009 Oct 22;114(17):3533-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
  • Approximately 5% to 10% of diffuse large B-cell lymphomas (DLBCLs) harbor an MYC oncogene rearrangement (MYC+).
  • Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Rearrangement. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult


17. Corti M, Carolis LD, Solari R, Villafañe MF, Schtirbu R, Lewi D, Narbaitz M: Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature. Braz J Infect Dis; 2010 Jan-Feb;14(1):81-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature.
  • Cutaneous B cell lymphoma (CBCL) is a lymphoproliferative disorder of neoplastic B cell of the skin with a wide range of clinical manifestations.
  • Skin is one of the common sites for extra-nodal lymphomas in patients with AIDS and B cell type is less common than T cell type.
  • Only recently, the existence of B cell lymphomas presenting clinically in the skin without evidence of extra-cutaneous involvement has been accepted as primary CBCL.
  • Two of them were primary cutaneous non-Hodgkin lymphomas.
  • All were CBCL; 3 were immunoblastic, 1 was plasmablastic, and the other was a Burkitt lymphoma.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisone / administration & dosage. Retrospective Studies. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428660.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Nomura S, Ishii K, Shimamoto Y, Yamamoto Y, Kadota E: Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier. Intern Med; 2006;45(4):215-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier.
  • A 71-year-old Japanese woman who was seropositive for T-lymphotropic virus type-1 (HTLV-1) developed primary Burkitt lymphoma of the uterus.
  • Biopsies from abdominal operation were diagnosed as Burkitt lymphoma.
  • Treatment was started with intensive chemotherapy according to a protocol for Burkitt lymphoma and mature-B cell leukemia.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / virology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16543692.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


19. Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood; 2006 Feb 1;107(3):1149-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.
  • Acute lymphoblastic leukemia (ALL) in adult patients is often resistant to current therapy, making the development of novel therapeutic agents paramount.
  • Lymphoblasts from adult patients with precursor B ALL were cultured on bone marrow stroma and were treated with CCI-779, a second generation MTI.
  • Treated cells showed a dramatic decrease in cell proliferation and an increase in apoptotic cells, compared to untreated cells.
  • We conclude that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Antibiot (Tokyo). 1984 Oct;37(10):1231-7 [6501094.001]
  • [Cites] J Antibiot (Tokyo). 1975 Oct;28(10):727-32 [1102509.001]
  • [Cites] Lancet. 1989 Jul 22;2(8656):227 [2568561.001]
  • [Cites] Science. 1991 Jan 18;251(4991):283-7 [1702904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4441-5 [8183928.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1116-23 [7913512.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):907-13 [9508172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5033-8 [9560223.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):143-9 [9720724.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):718-21 [9722298.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Stem Cells. 2004;22(6):1111-20 [15536200.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):525-37 [15728109.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2825-31 [15805283.001]
  • [Cites] Cancer Treat Rev. 1981 Mar;8(1):63-87 [7248995.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1614-20 [10995008.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Kidney Int. 2001 Jan;59(1):3-16 [11135052.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):249-58 [11566616.001]
  • [Cites] Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8 [11583941.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6172-80 [11593425.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2121-8 [11597394.001]
  • [Cites] Blood. 2002 Jul 15;100(2):654-60 [12091361.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2887-92 [12912932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):37-51 [14766125.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):657-66 [14770419.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2336-47 [15136596.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36490-6 [15218033.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1420-4 [15365568.001]
  • [Cites] Leuk Res. 1986;10(8):1007-13 [3528680.001]
  • (PMID = 16195324.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / K08 CA104882; United States / NCI NIH HHS / CA / K08 CA104882-01A1; United States / NCI NIH HHS / CA / CA82156; United States / NCI NIH HHS / CA / CA104882-01A1; United States / NCI NIH HHS / CA / CA96696
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 624KN6GM2T / temsirolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1895910
  •  go-up   go-down


20. Vaghefi P, Martin A, Prévot S, Charlotte F, Camilleri-Broët S, Barli E, Davi F, Gabarre J, Raphael M, Poirel HA: Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status. AIDS; 2006 Nov 28;20(18):2285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic abnormalities, known to play a major role in lymphomas of non-immunocompromised patients, are not well characterized in ARL.
  • Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.
  • CONCLUSION: This CGH study allowed the identification of non-random chromosomal alterations in ARL.
  • [MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117014.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


21. Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K: Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol; 2010 Dec;92(5):732-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
  • The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported.
  • In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Cancer Sci. 2008 Sep;99(9):1760-8 [18549405.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):133-8 [1985162.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2471-8 [1421370.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Blood. 2009 May 14;113(20):4834-40 [19264918.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):246-52 [18271922.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Int J Hematol. 2008 May;87(4):393-7 [18409079.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3713-20 [11389007.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):59-68 [16831590.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):935-40 [8622042.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Int J Hematol. 2008 Nov;88(4):443-7 [18855101.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):847-58 [3711961.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):77-82 [15723651.001]
  • (PMID = 21120644.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


22. Scheinfeld N: Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexate-induced skin eruptions. Dermatol Online J; 2006;12(7):15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / epidemiology. Choriocarcinoma / drug therapy. Female. HIV Infections / epidemiology. Humans. Male. Middle Aged. Pregnancy. Uterine Neoplasms / drug therapy

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459301.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Abortifacient Agents, Nonsteroidal; 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 28
  •  go-up   go-down


23. Cheson BD: Adult Burkitt lymphoma: too soon to declare victory. Oncology (Williston Park); 2008 Nov 30;22(13):1518-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma: too soon to declare victory.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2008 Nov 30;22(13):1508-17 [19133605.001]
  • (PMID = 19227573.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Liang CW, Li HY, Chang KP, Chen CK, Chen YL: HIV infection initially presenting as sinonasal Burkitt's lymphoma. Am J Otolaryngol; 2006 Nov-Dec;27(6):433-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection initially presenting as sinonasal Burkitt's lymphoma.
  • Burkitt's lymphoma is a common comorbidity of infection with the human immunodeficiency virus, but rarely the initial clinical manifestation of undiagnosed AIDS, especially for the otolaryngologist.
  • We report the case of a patient with recalcitrant rhinosinusitis subsequently diagnosed with sinonasal Burkitt's lymphoma and HIV.
  • [MeSH-major] Burkitt Lymphoma / radiography. HIV Infections / radiography. Sinusitis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Paranasal Sinuses / radiography. Rhinitis / diagnosis. Rhinitis / pathology. Tomography, X-Ray Computed


25. Strefford JC, Worley H, Barber K, Wright S, Stewart AR, Robinson HM, Bettney G, van Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, Saha V, Moorman AV, Harrison CJ: Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene; 2007 Jun 21;26(29):4306-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, approximately 30% of childhood and 50% of adult patients lack abnormalities with clinical relevance.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Profiling. Genome, Human. Leukemia-Lymphoma, Adult T-Cell / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Dosage. Humans. Infant. Male. Middle Aged. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237825.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. de Larrinoa AF, del Cura J, Zabala R, Fuertes E, Bilbao F, Lopez JI: Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma. J Clin Ultrasound; 2007 Jul-Aug;35(6):295-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma.
  • Five diagnostic categories were considered: large B-cell lymphomas (LBCL), small B-cell lymphomas (SBCL), Hodgkin's disease (HD), T cell lymphomas, and miscellaneous.
  • SBCL (39), LBCL (36), HD (15), T cell lymphomas (5), and miscellaneous (7) [including T cell-rich B cell (2), natural killer cell (1), Burkitt's lymphoma (1), and non-Hodgkin's lymphoma of the B cell type, NOS (3)] were correctly diagnosed.
  • Three HDs, 1 natural killer cell lymphoma, 1 follicular lymphoma, and 1 LBCL were not correctly diagnosed.
  • [MeSH-major] Biopsy / methods. Lymphoma / diagnosis. Ultrasonography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Female. Hodgkin Disease / diagnosis. Humans. Killer Cells, Natural / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 17486566.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Kojima M, Sakurai S, Morita Y, Nakamura N, Sugihara S, Shimano S: EBV(+) B-cell lymphoproliferative disorder associated with subsequent development of Burkitt lymphoma in a patient with idiopathic CD4(+) T-lymphocytopenia. J Clin Exp Hematop; 2008 Nov;48(2):55-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV(+) B-cell lymphoproliferative disorder associated with subsequent development of Burkitt lymphoma in a patient with idiopathic CD4(+) T-lymphocytopenia.
  • We report here a case of idiopathic CD4(+) T-lymphocytopenia (ICL) associated with Epstein-Barr virus (EBV)(+) lymphoproliferative disorder (LPD) terminating in Burkitt lymphoma (BL).
  • Biopsy of the specimen showed reactive lymph node hyperplasia and interfollicular B-cell hyperplasia.
  • [MeSH-major] Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / pathology. Lymphoproliferative Disorders / virology. T-Lymphocytopenia, Idiopathic CD4-Positive / pathology
  • [MeSH-minor] Adult. B-Lymphocytes / pathology. Biopsy. Flow Cytometry. Genes, Immunoglobulin Heavy Chain. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / pathology. Male. Nose Neoplasms / pathology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - T-Lymphocytopenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19039197.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med; 2006 Jun 8;354(23):2431-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of Burkitt's lymphoma.
  • BACKGROUND: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is crucial because these two types of lymphoma require different treatments.
  • We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • RESULTS: A classifier based on gene expression correctly identified all 25 pathologically verified cases of classic Burkitt's lymphoma.
  • Burkitt's lymphoma was readily distinguished from diffuse large-B-cell lymphoma by the high level of expression of c-myc target genes, the expression of a subgroup of germinal-center B-cell genes, and the low level of expression of major-histocompatibility-complex class I genes and nuclear factor-kappaB target genes.
  • Eight specimens with a pathological diagnosis of diffuse large-B-cell lymphoma had the typical gene-expression profile of Burkitt's lymphoma, suggesting they represent cases of Burkitt's lymphoma that are difficult to diagnose by current methods.
  • Among 28 of the patients with a molecular diagnosis of Burkitt's lymphoma, the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.
  • CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Gene Expression. Gene Expression Profiling. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bayes Theorem. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Genes, MHC Class I. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. NF-kappa B / genetics. Oligonucleotide Array Sequence Analysis. Survival Analysis. Transcription, Genetic. Translocation, Genetic


29. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer; 2006 Apr 1;106(7):1569-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
  • BACKGROUND: Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL.
  • CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


30. Butt FM, Chindia ML, Rana F, Machigo FG: Pattern of head and neck malignant neoplasms in HIV-infected patients in Kenya. Int J Oral Maxillofac Surg; 2008 Oct;37(10):907-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most commonly reported neoplasms of the head and neck region include Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL).
  • There is also an increased risk of oral squamous cell carcinoma (SCC).
  • A descriptive cross-sectional study including HIV-infected patients with neoplastic and non-neoplastic lesions was conducted.
  • The prevalence of neoplastic lesions in this study was 27%; 37 (68%) patients had KS, 9 (17%) had SCC, 7 (13%) had NHL and 1 (2%) had Burkitt's lymphoma.
  • In this study, the most common malignant neoplasms were KS, SCC and NHL, manifesting in a younger age group than in the non-HIV group of patients.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Burkitt Lymphoma / epidemiology. Candidiasis, Oral / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cheilitis / epidemiology. Cross-Sectional Studies. Female. Humans. Kenya / epidemiology. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Prevalence. Sarcoma, Kaposi / epidemiology. Sex Factors. Stomatitis, Aphthous / epidemiology. Young Adult


31. Kian TC, Miriam T, Richard Q, Peng YS, Li LE, Ivy S, Hwan-Cheong TL, Hua LH, Thye LS: Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk Lymphoma; 2008 Apr;49(4):824-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Asian Continental Ancestry Group. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398754.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


32. Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, Antonio García-Vela J, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A, Spanish Group for the Study of CNS Disease in NHL: Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol; 2009 Mar 20;27(9):1462-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.
  • PURPOSE: Here, we evaluate the sensitivity and specificity of a new 11-parameter flow cytometry (FCM) approach versus conventional cytology (CC) for detecting neoplastic cells in stabilized CSF samples from newly diagnosed aggressive B-cell non-Hodgkin's lymphoma (B-NHL) at high risk of CNS relapse, using a prospective, multicentric study design.
  • CC+/FCM+ samples typically had more than 20% neoplastic B cells and/or >or= one neoplastic B cell/microL, while FCM+/CC- samples showed lower levels (P < .0001) of infiltration.
  • Interestingly, in Burkitt lymphoma, presence of CNS disease by FCM could be predicted with a high specificity when increased serum beta2-microglobulin and neurological symptoms coexisted, while peripheral blood involvement was the only independent parameter associated with CNS disease in diffuse large B-cell lymphoma, with low predictive value.
  • [MeSH-major] Flow Cytometry / methods. Lymphoma, B-Cell / cerebrospinal fluid. Meningeal Neoplasms / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. B-Lymphocytes / pathology. Female. Humans. Leukocytes / pathology. Male. Middle Aged. Sensitivity and Specificity. Young Adult

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Rodríguez-Otero P; Pérez-Ceballos E; Monteserin MC; Diaz-Arias J; Pérez M; Domingo-Domenech E; Poderós C; Provencio M; Vallejo C; Forés R; Gómez E; de la Cruz M; Palacios A; Fernández S; Marin M; Hernández JA; Molero T; Romero-Picos E; Mateos MC; Peñarrubia M; Caballero D; Conde E
  •  go-up   go-down


33. Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S, Schwaenen C, Wessendorf S, Spang R, Möller P, Hansmann ML, Bernd HW, Ott G, Hummel M, Stein H, Loeffler M, Trümper L, Zimmermann M, Reiter A, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe: Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood; 2008 Aug 15;112(4):1374-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials.
  • The spectrum of entities, the therapeutic strategy, and the outcome of mature aggressive B-cell non-Hodgkin lymphomas (maB-NHLs) differs between children and adolescents on the one hand and adult patients on the other.
  • Whereas adult maB-NHLs have been studied in detail, data on molecular profiling of pediatric maB-NHLs are hitherto lacking.
  • We compared this group to a series of 182 previously published cases of adult maB-NHL.
  • Gene expression profiling reclassified 31% of morphologically defined diffuse large B-cell lymphomas as molecular Burkitt lymphoma (mBL).
  • No differences were detectable between pediatric and adult mBL with regard to gene expression or chromosomal imbalances.
  • [MeSH-major] Gene Expression Profiling. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Clinical Trials as Topic. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Male. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509088.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Coche D, Bergues B, Harrivel V, Guillaume N: [Biphenotypic acute leukaemia with Burkitt-like cytology]. Ann Biol Clin (Paris); 2009 Jul-Aug;67(4):437-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biphenotypic acute leukaemia with Burkitt-like cytology].
  • [Transliterated title] Leucémie aiguë biphénotypique avec aspect cytologique de type Burkitt.
  • Biphenotypic acute leukaemia (BAL) represents about 5% of adult acute leukaemia.
  • Here, we report the case of a BAL with Burkitt-like cytology, corresponding to "the acute lymphoblastic leukaemia, Burkitt type" L3 for the FAB classification.
  • [MeSH-minor] Adult. Blast Crisis / pathology. Burkitt Lymphoma / pathology. Flow Cytometry / methods. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19654084.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


35. Alici-Evcimen Y, Breitbart WS: Ifosfamide neuropsychiatric toxicity in patients with cancer. Psychooncology; 2007 Oct;16(10):956-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Burkitt Lymphoma / drug therapy. Ifosfamide / adverse effects. Neurotoxicity Syndromes / etiology. Psychoses, Substance-Induced / etiology
  • [MeSH-minor] Adult. Delusions / chemically induced. Enzyme Inhibitors / therapeutic use. Female. Humans. Methylene Blue / therapeutic use. Prognosis

  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 John Wiley & Sons, Ltd.
  • (PMID = 17278152.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Enzyme Inhibitors; T42P99266K / Methylene Blue; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 17
  •  go-up   go-down


36. Bellaaj H, Amouri H, Gouiaa N, Elloumi M, Hdiji S, Trabelsi K, Makni S, Guermazi M, Souissi T: [Burkitt's lymphoma revealed by an ovarian tumour]. Tunis Med; 2008 Aug;86(8):768-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt's lymphoma revealed by an ovarian tumour].
  • [Transliterated title] Lymphome de Burkitt révéle par une tumeur ovarienne.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472769.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Tunisia
  •  go-up   go-down


37. Keller C, Savage DG, Rusta-Villa M, Bhagat G, Alobeid B: Primary Burkitt lymphoma of the uterine corpus. Leuk Lymphoma; 2006 Jan;47(1):141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Burkitt lymphoma of the uterine corpus.
  • This study reports the first well-documented case of sporadic Burkitt lymphoma arising in and confined to the uterine corpus in a 40-year-old woman who presented with vaginal bleeding.
  • Endometrial curettings showed a diffuse infiltrate of medium sized lymphocytes with the characteristic morphologic and immunophenotypic features of Burkitt lymphoma.
  • This report demonstrates that Burkitt lymphoma can present as isolated, organ confined disease at unusual sites and with protean symptoms.
  • [MeSH-major] Burkitt Lymphoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Humans. Hysterectomy. In Situ Hybridization, Fluorescence / methods. Sensitivity and Specificity. Translocation, Genetic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321839.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S: Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia; 2009 Nov;23(11):2090-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
  • Unfortunately, however, tumors including adult T-cell leukemia/lymphoma (ATL) have disadvantages such as p53 mutations and a lack of p16(INK4a) and/or p14(ARF).
  • In this study we characterized Nutlin-3a-induced cell death in 16 leukemia/lymphoma cell lines.
  • Eight cell lines, including six ATL-related cell lines, had wild-type p53 and Nutlin-3a-activated p53, and the cell lines underwent apoptosis or cell-cycle arrest, whereas eight cell lines with mutated p53 were resistant.
  • Interestingly, senescence-associated-beta-galactosidase (SA-beta-gal) staining revealed that only ATL-related cell lines with wild-type p53 showed cellular senescence, although they lack both p16(INK4a) and p14(ARF).
  • These results indicate that cellular senescence is an important event in p53-dependent cell death in ATL cells and is inducible without p16(INK4a) and p14(ARF).
  • Furthermore, knockdown of Tp53-induced glycolysis and apoptosis regulator (TIGAR), a novel target gene of p53, by small interfering RNA(siRNA) indicated its important role in the induction of cellular senescence.
  • [MeSH-major] Apoptosis / drug effects. Imidazoles / pharmacology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Piperazines / pharmacology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Cell Aging / drug effects. Cell Cycle / drug effects. Cell Line, Transformed. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Drug Synergism. Humans. Intracellular Signaling Peptides and Proteins / genetics. Jurkat Cells. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. RNA, Small Interfering. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Tumor Suppressor Protein p14ARF / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19710698.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / C12orf5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Imidazoles; 0 / Intracellular Signaling Peptides and Proteins; 0 / Piperazines; 0 / RNA, Small Interfering; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


39. Cornejo-Juárez P, Volkow-Fernández P, Avilés-Salas A, Calderón-Flores E: AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico. Rev Invest Clin; 2008 Sep-Oct;60(5):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
  • BACKGROUND: Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS.
  • RESULTS: Eighty seven HIV-positive patients were diagnosed with NHL (diffuse large B-cell lymphoma n=69; Burkitt-like n=8; pleomorphic large cell n=7; low-grade n=2, and angiocentric n=1).
  • Overall, 38 patients (43.7%) achieved complete response to NHL therapy, including only 14.3% patients in the non-HAART compared with 57.6% in the HAART group (p < or = 0.0001).
  • Two patients (7.1%) in the non-HAART were alive compared with 37 (63.8%) in the HAART group (p < or = 0.0001).
  • [MeSH-major] Cancer Care Facilities / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Mexico / epidemiology. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227434.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


40. Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J: NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol; 2008 Jan;36(1):69-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
  • OBJECTIVE: Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism in the clinical activity of rituximab for treatment of B-cell malignancies.
  • We have studied the in vitro effect of NK stimulators, such as interleukin-15 (IL-15) and CpG oligodeoxynucleotides A-Class (CpG ODN A), in the enhancement of rituximab-mediated ADCC against B-cell lymphoma.
  • METHODS: Peripheral blood mononuclear cells (PBMC), purified NK cells, or NK-depleted PBMC from healthy donors, were activated with IL-15 or CpG ODN A, and cocultured with B-lymphoma cells in the presence of rituximab to evaluate the enhancement of the cytotoxicity.
  • Furthermore, IL-15 or CpG ODN A-activated PBMC, but not activated purified NK cells, secreted large amounts of interferon-gamma in the presence of rituximab-coated lymphoma cells.
  • CONCLUSIONS: IL-15 and CpG ODN A enhance rituximab-mediated ADCC against B-cell lymphoma.
  • These findings suggest that these agents could be used as adjuvants in combination with rituximab for patients with B-cell lymphoma.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Antibodies, Monoclonal / pharmacology. Antibody-Dependent Cell Cytotoxicity / drug effects. Burkitt Lymphoma / pathology. Interleukin-15 / pharmacology. Killer Cells, Natural / drug effects. Leukocytes, Mononuclear / drug effects. Oligodeoxyribonucleotides / pharmacology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cell Line, Tumor / drug effects. Drug Synergism. Humans. Interferon-gamma / biosynthesis. Lymphocyte Activation / drug effects. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17959301.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / CpG ODN 2216; 0 / Interleukin-15; 0 / Oligodeoxyribonucleotides; 4F4X42SYQ6 / Rituximab; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


41. Tauro S, Cochrane L, Lauritzsen GF, Baker L, Delabie J, Roberts C, Mahendra P, Holte H: Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (&lt;50 years): a comparison of two adapted BFM protocols. Am J Hematol; 2010 Apr;85(4):261-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
  • The chemotherapy dose-intensity in two adapted German BFM paediatric protocols (BFM 90 and NHL 86) was compared in contemporaneously treated adults <50 years with Burkitt lymphoma and B-cell lymphoma unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (collectively referred to as BL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisolone / administration & dosage. Survival Analysis. Vincristine / administration & dosage. Vindesine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201088.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


42. Haque T, Johannessen I, Dombagoda D, Sengupta C, Burns DM, Bird P, Hale G, Mieli-Vergani G, Crawford DH: A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. J Infect Dis; 2006 Sep 1;194(5):584-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purified 72A1 MAb was infused into 1 healthy adult and 4 EBV-seronegative children after liver transplant.
  • No adverse reactions were seen in the adult or in 3 of the transplant recipients.
  • [MeSH-minor] Adult. Animals. Burkitt Lymphoma / immunology. Burkitt Lymphoma / prevention & control. Humans. Mice. Mice, SCID

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897655.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


43. Bociek RG: Adult Burkitt's lymphoma. Clin Lymphoma; 2005 Jun;6(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt's lymphoma.
  • Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the gastrointestinal tract and central nervous system.
  • This subtype of non-Hodgkin's lymphoma is associated with unique cytogenetic translocations involving the c-MYC oncogene on chromosome 8, which appears to be involved in the pathogenesis of this disease.
  • Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy regimens.
  • The use of autologous stem cell transplantation appears to benefit patients who have had chemotherapy-sensitive relapses.
  • The role of allogeneic stem cell transplantation for this disease remains uncertain.
  • Patients with HIV-associated Burkitt's lymphoma appear to have a better prognosis today, which is likely a result of more effective antiretroviral therapy and the ability to treat selected patients with more aggressive chemotherapeutic regimens than before.
  • This article will review the epidemiologic, biologic, diagnostic, and therapeutic aspects of Burkitt's lymphoma in adults.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Humans

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989701.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


44. Matsuno N, Hoshino K, Nanri T, Kawakita T, Suzushima H, Kawano F, Mitsuya H, Asou N: p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia. Leuk Res; 2005 May;29(5):557-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia.
  • To examine pathologic and clinical significance of the p15 gene inactivation, we established a quantitative assay of p15 mRNA expression in the bone marrow cells by real-time quantitative reverse transcriptase-polymerase chain reaction. p15 mRNA expression in 14 patients with precursor B-cell acute lymphoblastic leukemia (PBC-ALL) well correlated with status of deletion and methylation in the p15 gene analyzed by Southern blotting.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. DNA Methylation. Gene Expression Regulation, Leukemic. Leukemia, Myeloid / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Messenger / metabolism. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Cell Lineage. CpG Islands. Cyclin-Dependent Kinase Inhibitor p15. Humans. Reverse Transcriptase Polymerase Chain Reaction. Sequence Deletion. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755508.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


45. Gentile S, Messina M, Rainero I, Lo Giudice R, De Martino P, Pinessi L: Miller Fisher syndrome associated with Burkitt's lymphoma. Eur J Neurol; 2006 Apr;13(4):430
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Miller Fisher syndrome associated with Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / complications. Kidney Neoplasms / complications. Miller Fisher Syndrome / etiology. Paraneoplastic Syndromes / physiopathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Gangliosides / immunology. Herpesvirus 4, Human. Humans. Immunoglobulins, Intravenous / therapeutic use. Kidney Transplantation. Male. Tumor Virus Infections / complications. Ureter / abnormalities


46. Queiroga EM, Gualco G, Chioato L, Harrington WJ, Araujo I, Weiss LM, Bacchi CE: Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8. Am J Clin Pathol; 2008 Aug;130(2):186-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.
  • Kaposi sarcoma-associated herpesvirus, or human herpesvirus 8 (HHV-8), infects a wide range of normal cells, having a well-established role in the pathogenesis of various neoplasms, including Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman disease (MCD) and MCD-associated plasmablastic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Aug;19(8):1391-8 [15973450.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):834-7 [16136049.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1269-70 [10534180.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):559-60 [11797191.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Arch Dermatol. 1998 Jun;134(6):751 [9645650.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):21-7 [15660651.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]
  • (PMID = 18628086.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS125501; NLM/ PMC2718775
  •  go-up   go-down


47. Chennupati SK, Govindaraj S, Setzen G, Chiu AG: Adult Burkitt lymphoma originating in the sphenoid sinus: case report and review of the literature. Ear Nose Throat J; 2009 Jul;88(7):E07
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma originating in the sphenoid sinus: case report and review of the literature.
  • Burkitt lymphoma is a high-grade B-cell non-Hodgkin lymphoma.
  • The presence of any type of lymphoma in the paranasal sinuses is rare.
  • We report a case of Burkitt lymphoma that originated in the sphenoid sinus in a 66-year-old white woman.
  • An endoscopic sphenoidotomy was performed to obtain a tissue specimen, and a diagnosis of sporadic Burkitt lymphoma was established on the basis of its clinical, morphologic, and immunohistochemical characteristics.
  • This case is one of the few reported cases of true adult Burkitt lymphoma originating in the sphenoid sinus.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Sphenoid Sinus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623516.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


48. Xiao C, Su ZL, Wu QL, Gao HY, Fang JC, Xia ZJ, Guan ZZ: [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2005 Jan;34(1):22-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
  • OBJECTIVE: To investigate the clinical and pathological features of non-Hodgkin's lymphoma (NHL) and to evaluate the applicability of the new WHO classification of lymphoid neoplasms.
  • METHODS: According to the new WHO classification, a total of 500 cases of non-Hodgkin's lymphoma diagnosed during the period 1992 - 2003 were reviewed and reappraised with their morphological, immunological and clinical characteristics.
  • RESULTS: Among 500 cases previously diagnosed as lymphomas, 493 cases (98.6%) were confirmed to be NHL, of which B-cell neoplasms was 69.0% and T/NK-cell neoplasms 29.8%.
  • Overall, 6 subtypes including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), unspecified peripheral T-cell lymphoma (PT-un), precursor T-lymphoblastic lymphoma (T-LBL), extranodal marginal zone B-cell lymphoma of MALT type (MALT) and B-small lymphocytic lymphoma (B-SLL) were among the most common subtypes.
  • In pediatric and young patient populations, the most common subtypes were LBL, DLBCL and Burkitt's lymphoma.
  • Marginal zone B-cell lymphoma and SLL demonstrated the best prognosis, LBL and PT-un both the worst, whereas DLBCL and FL had an intermediate prognosis, however, subgrouping of FL according to WHO classification did not reveal a significant survival difference (P > 0.05).
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. China / epidemiology. Female. Humans. Killer Cells, Natural. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / classification. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796877.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


49. Kempeneers C, Forget P, Dresse MF, Guidi O, Schmitz V, Jamblin P, Bostem H, Closon MT, Demarche M, Erpicum P, Hoyoux C: [Retrospective study of childhood lymphomas. Report of 27 children treated at a single institution]. Rev Med Liege; 2005 Nov;60(11):855-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Childhood lymphomas represent a heterogeneous group of disorders that are quite different from adult lymphomas.
  • The five-year overall survival for the entire group is more than 95 %; the 5-year disease free survival is 91,6 % for Hodgkin's lymphomas, 92,8% for non Hodgkin's lymphomas and 100% for Burkitt diseases.
  • [MeSH-major] Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402530.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


50. Tholouli E, Watt S, Lucas GS, Burthem J, Yin JA, Cavet J, Greenfield H, Houghton JB: Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome. Blood; 2009 Jul 9;114(2):485-6; author reply 486-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome.
  • [MeSH-major] Bone Marrow / metabolism. Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cytogenetics. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • (PMID = 19589933.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


51. Rehbinder B, Wullstein Ch, Bechstein WO, Probst M, Engels K, Kriener S, Döbert N, Schwarz W, Brixner V, Steffan D, Gauer S, Geiger H, Hauser IA: Epstein-barr virus-associated posttransplant lymphoproliferative disorder of donor origin after simultaneous pancreas-kidney transplantation limited to pancreas allograft: A case report. Am J Transplant; 2006 Oct;6(10):2506-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, screening for EBV-associated lymphoma was negative.
  • After an 18F-Fluorodeoxyglucose positron emission tomography positive signal and an abnormal computed tomography scan of the pancreas transplant, a biopsy revealed a diffuse large monomorphic B-cell lymphoma, which was confined to the grafted organ.
  • Subsequent to the intervention, fever disappeared, EBV DNA became undetectable and lymphoma screening remained negative.
  • [MeSH-major] Burkitt Lymphoma / etiology. Kidney Transplantation / adverse effects. Pancreas Transplantation / adverse effects
  • [MeSH-minor] Adult. Biopsy. DNA, Viral / analysis. Diabetes Mellitus, Type 1 / surgery. Diagnosis, Differential. Follow-Up Studies. Herpesvirus 4, Human / genetics. Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16869797.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


52. Knowles JW, Elliott AB, Brody J: A case of complete heart block reverting to normal sinus rhythm after treatment for cardiac invasive Burkitt's lymphoma. Ann Hematol; 2007 Sep;86(9):687-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of complete heart block reverting to normal sinus rhythm after treatment for cardiac invasive Burkitt's lymphoma.
  • [MeSH-major] Arrhythmia, Sinus / etiology. Burkitt Lymphoma / complications. Burkitt Lymphoma / drug therapy. Heart Block / etiology. Heart Neoplasms / complications. Heart Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections. Humans. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiol. 1999 Dec;34(6):345-9 [10642932.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Echocardiography. 2003 Feb;20(2):201-2 [12848690.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Br Heart J. 1975 Jan;37(1):94-7 [1111565.001]
  • [Cites] Int Heart J. 2005 Sep;46(5):927-31 [16272785.001]
  • [Cites] Eur Heart J. 1994 Mar;15(3):407-8 [8013520.001]
  • [Cites] Clin Cardiol. 1996 Mar;19(3):262-4 [8674270.001]
  • [Cites] Cardiology. 1997 Nov-Dec;88(6):613-6 [9397321.001]
  • [Cites] Am J Hematol. 1998 Oct;59(2):171-4 [9766804.001]
  • [Cites] Br J Dis Chest. 1978 Jan;72(1):71-3 [623707.001]
  • (PMID = 17410366.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL087647; United States / NHLBI NIH HHS / HL / R01 HL087647-02
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Other-IDs] NLM/ NIHMS151806; NLM/ PMC4031916
  •  go-up   go-down


53. Onciu M, Schlette E, Zhou Y, Raimondi SC, Giles FJ, Kantarjian HM, Medeiros LJ, Ribeiro RC, Pui CH, Sandlund JT: Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer; 2006 Sep 1;107(5):1084-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma.
  • BACKGROUND: Karyotypic abnormalities in sporadic Burkitt lymphoma (BL) have been described extensively.
  • However, to the authors' knowledge, very limited studies have focused on the secondary chromosomal abnormalities in pediatric BL as compared with those of adult BL and on their prognostic impact.
  • METHODS: A retrospective analysis was performed in all pediatric and adult patients at 2 institutions, with a morphologic diagnosis of BL, pretherapy tumor karyotype available, and t(8;14), t(8;22), or t(2;8) present.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Prognosis. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862570.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Tanabe Y, Muraoka A, Ryu T, Saito T: [Acquired immunodeficiency syndrome associated with Burkitt's leukemia diagnosed by ileus]. Nihon Naika Gakkai Zasshi; 2008 Jan 10;97(1):150-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acquired immunodeficiency syndrome associated with Burkitt's leukemia diagnosed by ileus].
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ileus / etiology. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283903.001).
  • [ISSN] 0021-5384
  • [Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
  • [ISO-abbreviation] Nippon Naika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Alonso-Pérez A, Fraga J, Delgado Y, Aragüés M, Nam-Cha S, García-Díez A: Nodular herpes zoster with herpetic syringitis and no epidermal involvement in a patient with Burkitt lymphoma. Am J Dermatopathol; 2006 Jun;28(3):194-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular herpes zoster with herpetic syringitis and no epidermal involvement in a patient with Burkitt lymphoma.
  • We report the case of a woman with Burkitt lymphoma who developed 2 nodular, asymptomatic lesions while receiving treatment with chemotherapy and radiotherapy for her hematological disease.
  • [MeSH-major] Burkitt Lymphoma / pathology. Eccrine Glands / pathology. HIV Infections / pathology. Herpes Zoster / pathology. Herpesvirus 3, Human. Skin Diseases, Viral / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Dermis / pathology. Dermis / virology. Epidermis / pathology. Epidermis / virology. Epithelium / pathology. Epithelium / virology. Female. Humans


56. Escher R, Wilson P, Carmichael C, Suppiah R, Liu M, Kavallaris M, Cannon P, Michaud J, Scott HS: A pedigree with autosomal dominant thrombocytopenia, red cell macrocytosis, and an occurrence of t(12:21) positive pre-B acute lymphoblastic leukemia. Blood Cells Mol Dis; 2007 Jul-Aug;39(1):107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pedigree with autosomal dominant thrombocytopenia, red cell macrocytosis, and an occurrence of t(12:21) positive pre-B acute lymphoblastic leukemia.
  • Here we describe a new autosomal dominant inherited phenotype of thrombocytopenia and red cell macrocytosis in a four-generation pedigree.
  • Tri-lineage involvement of platelets, red cells and white cells may suggest a genetic defect in an early multiliear progenitor or a stem cell.
  • Functional assays in EBV-transformed cell lines revealed a defect in cell proliferation and tubulin dynamics.
  • [MeSH-major] Anemia, Macrocytic / genetics. Burkitt Lymphoma / genetics. Chromosome Disorders / genetics. Genetic Predisposition to Disease. Pedigree. Thrombocytopenia / genetics
  • [MeSH-minor] Adult. Child, Preschool. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 21 / genetics. Core Binding Factor Alpha 2 Subunit. Family. Female. Genes, Dominant. Hematopoiesis / genetics. Humans. Infant. Male. Middle Aged. Nuclear Proteins. Transcription Factors. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434765.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Nuclear Proteins; 0 / RUNX1 protein, human; 0 / Transcription Factors; 0 / ZFPM1 protein, human
  •  go-up   go-down


57. Vives S, Sancho JM, Juncà J, Grifols JR, Morgades M, Ribera JM: [High-dose ifosfamide and etoposide regimen as salvage and mobilization therapy for patients with lymphoma]. Med Clin (Barc); 2008 Feb 16;130(5):172-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose ifosfamide and etoposide regimen as salvage and mobilization therapy for patients with lymphoma].
  • PATIENTS AND METHOD: Twenty-four patients with relapsed or refractory lymphoma received IFOVM and G-CSF.
  • The histologyc subtypes of lymphoma were: diffuse large B cell (DLBCL) (n = 15), Hodgkin (n = 2), Burkitt (n = 2), mantle cell (n = 2), anaplastic (n = 1), peripheral T-cell (n = 1) and follicular (n = 1).
  • The median time to achieve granulocyte cell count > 1 x 10(9)/l and platelet count > 20 x 10(9)/l was 15 and 16 days, respectively.
  • CONCLUSIONS: The regimen IFOVM and G-CSF allows an effective peripheral blood stem cells mobilization in patients with lymphoma, particularly in those with DLBCL, but it is associated with significant toxicity.
  • [MeSH-major] Etoposide / administration & dosage. Hematopoietic Stem Cell Mobilization. Ifosfamide / administration & dosage. Lymphoma / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341831.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


58. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, Dastugue N, Brousset P: A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood; 2007 Apr 15;109(8):3417-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
  • We report a novel t(7;9)(q11;p13) translocation in 2 patients with B-cell acute lymphoblastic leukemia (B-ALL).
  • After cloning the full-length cDNA of the chimeric gene, confocal microscopy of transfected NIH3T3 cells and Burkitt lymphoma cells (DG75) demonstrated that PAX5-ELN was localized in the nucleus.
  • Since PAX5 is essential for B-cell differentiation, this translocation may account for the blockage of leukemic cells at the pre-B-cell stage.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. Elastin / genetics. Genes, Dominant. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Animals. Antigens, CD19 / biosynthesis. Antigens, CD19 / genetics. Cell Differentiation / genetics. Cell Nucleus / genetics. Cell Nucleus / metabolism. Cell Nucleus / pathology. HeLa Cells. Humans. Male. Mice. NIH 3T3 Cells. Promoter Regions, Genetic / genetics. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179230.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human; 9007-58-3 / Elastin
  •  go-up   go-down


59. Bellier C, Khellaf M, Lambotte O, Godeau B: [Burkitt's lymphoma in a patient with systemic lupus erythematosus treated with immunosuppressive drugs. A case report]. Rev Med Interne; 2006 Mar;27(3):244-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt's lymphoma in a patient with systemic lupus erythematosus treated with immunosuppressive drugs. A case report].
  • [Transliterated title] Lymphome de Burkitt au cours d'un lupus systémique traité par immunosuppresseurs. A propos d'un cas.
  • However, the pathophysiological link between lymphoma and SLE is still a matter of debate.
  • We report a new case of Burkitt's lymphoma occurring in a patient treated with immunosuppressive drugs for SLE.
  • A bone marrow biopsy revealed Burkitt's lymphoma.
  • CONCLUSION: This is the third case reported of Burkitt's lymphoma occurring in SLE.
  • Here we discuss the data of the literature and the possible pathophysiological links between Burkitt's lymphoma and SLE.


60. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R: Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1183-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.
  • PURPOSE: Patients with chemotherapy-resistant lymphoma have rapidly progressive disease and a poor prognosis.
  • The histologic features at diagnosis were follicular in 11 (Grade 1 in 4, Grade 2 in 3, and Grade 3 in 4), diffuse large B-cell in 14, peripheral T-cell lymphoma in 2, Burkitt-like in 1, mantle cell in 2, natural killer cell in 2, plasmacytoma/lymphoma in 1, and T-cell lymphoblastic in 1.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose Fractionation. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Remission Induction. Survivors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376490.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P: Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol; 2006 Jan;19(1):25-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified 14 B-cell neoplasms with concurrent t(14;18) and chromosome 8q24 or c-MYC translocations shown by conventional cytogenetics or fluorescence in situ hybridization analysis.
  • None of these patients had a history of follicular lymphoma.
  • Morphologically, nine neoplasms had features of Burkitt or atypical Burkitt lymphoma/leukemia and three were diffuse large B-cell lymphoma with high-grade cytologic features.
  • The remaining two cases were plasmablastic myeloma and low-grade B-cell lymphoma, respectively.
  • The proliferation index assessed by using Ki-67 (MIB1) was 5% in the low-grade B-cell lymphoma, 80% in the plasmablastic myeloma, 90-95% in three cases of diffuse large B-cell lymphoma, and ranged from 90 to >99% in most Burkitt and atypical Burkitt neoplasms.
  • The patient with low-grade B-cell lymphoma was treated with rituximab.
  • We conclude that most B-cell lymphomas with concurrent t(14;18) and 8q24/c-MYC translocations fall within the morphologic spectrum of diffuse large B-cell and Burkitt lymphoma.
  • However, this combination of molecular abnormalities can also rarely occur in other neoplasms, such as the cases of low-grade B-cell lymphoma and plasmablastic myeloma in this study.
  • [MeSH-major] Lymphoma / pathology. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / analysis. Antigens, CD5 / analysis. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. Burkitt Lymphoma / pathology. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Ki-67 Antigen / analysis. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Neprilysin / analysis. Prognosis. Proto-Oncogene Proteins c-bcl-2 / analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258503.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD5; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


62. Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ, Children's Oncology Study Group: Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol; 2007 Sep;29(9):627-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Asparaginase / therapeutic use. Bacterial Proteins / therapeutic use. Burkitt Lymphoma / drug therapy. Escherichia coli / enzymology. Hypersensitivity / immunology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Erwinia / enzymology. Humans. Infant. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Allergy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Sep;29(9):587-8 [17805029.001]
  • (PMID = 17805038.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-03161; United States / NCI NIH HHS / CA / CA-05587; United States / NCI NIH HHS / CA / CA-07431; United States / NCI NIH HHS / CA / CA-11233; United States / NCI NIH HHS / CA / CA-15525; United States / NCI NIH HHS / CA / CA-15898; United States / NCI NIH HHS / CA / CA-15989; United States / NCI NIH HHS / CA / CA-20549; United States / NCI NIH HHS / CA / CA-25408; United States / NCI NIH HHS / CA / CA-28383; United States / NCI NIH HHS / CA / CA-28439; United States / NCI NIH HHS / CA / CA-28476; United States / NCI NIH HHS / CA / CA-29139; United States / NCI NIH HHS / CA / CA-29293; United States / NCI NIH HHS / CA / CA-29691; United States / NCI NIH HHS / CA / CA-30969; United States / NCI NIH HHS / CA / CA-31566; United States / NCI NIH HHS / CA / CA-32053; United States / NCI NIH HHS / CA / CA-33587; United States / NCI NIH HHS / CA / CA-33603; United States / NCI NIH HHS / CA / CA-33625; United States / NCI NIH HHS / CA / CA-53128; United States / NCI NIH HHS / CA / CA-69177; United States / NCI NIH HHS / CA / CA-69428
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


63. Bendall LJ, Baraz R, Juarez J, Shen W, Bradstock KF: Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res; 2005 Apr 15;65(8):3290-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chemokine stromal-derived factor-1alpha (SDF-1alpha) regulates leukemic cell motility and proliferation; however, the importance of these functions in the growth and dissemination of leukemia is unclear.
  • This study suggests that signaling through p38 MAPK is required for ALL cell chemotaxis but not for proliferation, and that the loss of a chemotactic response to SDF-1alpha does not impede engraftment in NOD/SCID mice.
  • [MeSH-major] Burkitt Lymphoma / enzymology. Burkitt Lymphoma / pathology. Chemokines, CXC / pharmacology. Chemotaxis, Leukocyte / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Animals. B-Lymphocytes / drug effects. B-Lymphocytes / pathology. Calcium / metabolism. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Chemokine CXCL12. Child. Child, Preschool. Female. Humans. Infant. Integrin alpha4beta1 / metabolism. Integrin alpha5beta1 / metabolism. MAP Kinase Signaling System / drug effects. Male. Mice. Mice, Inbred NOD. Mice, SCID. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833862.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Integrin alpha4beta1; 0 / Integrin alpha5beta1; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; SY7Q814VUP / Calcium
  •  go-up   go-down


64. Unholzer A, Starz H, Hirschsteiner O, Balda BR: [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient]. J Dtsch Dermatol Ges; 2005 Jan;3(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient].
  • [Transliterated title] Burkitt-Lymphom der Gingiva bei einem Hepatitis C-positiven nierentransplantierten Patienten.
  • Compared to the general population, the organ transplant patients have a 30-60 fold increased risk of developing non-Hodgkin's lymphoma.
  • A 55-year-old, hepatitis C-positive man developed an Epstein-Barr virus (EBV)- negative Burkitt lymphoma (BL) first appearing on the gingiva under immunosuppressive therapy nine years after allogenic renal transplantation.
  • [MeSH-major] Burkitt Lymphoma / etiology. Gingival Neoplasms / etiology. Hepatitis C / complications. Immunocompromised Host. Kidney Transplantation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Gingiva / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Time Factors. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353750.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


65. Lam MS: Treatment of Burkitt's lymphoma during pregnancy. Ann Pharmacother; 2006 Nov;40(11):2048-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Burkitt's lymphoma during pregnancy.
  • OBJECTIVE: To report a case of both successful maternal treatment outcome and normal fetal outcome in a patient who was diagnosed with Burkitt's lymphoma (BL) and aggressively treated with 6 different chemotherapy agents during the second and third trimesters of pregnancy.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Infant, Newborn. Male. Methotrexate / therapeutic use. Pregnancy. Registries. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062832.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


66. Magrath IT: Treatment of Burkitt lymphoma in children and adults: Lessons from Africa. Curr Hematol Malig Rep; 2006 Dec;1(4):230-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Burkitt lymphoma in children and adults: Lessons from Africa.
  • Modern chemotherapy for childhood Burkitt lymphoma has its origins in Africa, where treatment evolved from one or two doses of single agents, which were curative in some patients, to combinations of non-cross-resistant drugs.
  • Therapy regimens for adults with Burkitt lymphoma have been developed by modifying second-generation pediatric protocols, and few investigators have used the third-generation pediatric regimens that include higher doses of methotrexate and additional agents.
  • The weight of evidence strongly suggests that high-dose therapy with stem cell rescue in first remission cannot substitute for intensive therapy from the outset.
  • Because childhood diffuse large-B-cell leukemia (DLBCL) responds equally well to therapy for Burkitt lymphoma, more intensive therapy and intensive support might also give better results in at least a subset of adults with advanced DLBCL-perhaps defined on the basis of limited molecular profiling, which has provided new information about the categories of aggressive B-cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Age Factors. Anthracyclines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Central Nervous System / pathology. Child. Diagnosis, Differential. Drug Therapy / trends. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / administration & dosage. Randomized Controlled Trials as Topic / statistics & numerical data. Rituximab. Salvage Therapy. Treatment Outcome. Uganda / epidemiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1967 May;20(5):756-9 [6024288.001]
  • [Cites] Br Med J. 1967 Nov 11;4(5575):323-7 [6053614.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] N Engl J Med. 1977 Jul 14;297(2):75-80 [865579.001]
  • [Cites] Onkologie. 1986 Apr;9(2):126-30 [3520421.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Med Pediatr Oncol. 2001 Nov;37(5):432-41 [11745871.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1507-15 [6244085.001]
  • [Cites] Blood. 1984 May;63(5):1102-11 [6546890.001]
  • [Cites] Cancer. 1978 Mar;41(3):1059-63 [638947.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):538-9 [14998863.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(1):11-8 [3153214.001]
  • [Cites] Leukemia. 2005 Apr;19(4):659-63 [15716988.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:77-81 [9187436.001]
  • [Cites] Int J Cancer. 1972 Sep 15;10(2):254-61 [4574467.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):240-8 [8558204.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):133-8 [1985162.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1973-82 [1941056.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):115-21 [15350300.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):353-8 [14735176.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] Ann Oncol. 1995 May;6(5):445-51 [7545428.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4244 [14623773.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1928-35 [16284057.001]
  • [Cites] Med Oncol. 2005;22(3):257-67 [16110137.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):33-9; discussion 45-8 [9578060.001]
  • [Cites] Blood. 1988 Aug;72(2):792-5 [3401598.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):285-91 [11900213.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Summer;13(2):222-46 [2069232.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3713-20 [11389007.001]
  • [Cites] Leuk Res. 1980;4(1):33-59 [6968008.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Int J Cancer. 1976 Apr 15;17(4):436-40 [776840.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] JAMA. 1972 Nov 27;222(9):1166 [4678054.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Br Med J. 1971 Aug 26;3(5773):508-12 [5109411.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):211-9 [1703226.001]
  • [Cites] Am J Med. 1975 Mar;58(3):314-21 [1115074.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):661-5 [2313335.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):445-9 [15653703.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1977 Jun;16(3):225-31 [906892.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):815-20 [15352985.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Hematol Oncol. 1991 Jul-Oct;9(4-5):267-74 [1743629.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2465-72 [8823324.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] Cancer. 1976 Sep;38(3):1043-51 [782684.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Cancer. 1970 Aug;26(2):474-84 [5468593.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2578-615 [6082297.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Haematol Blood Transfus. 1977;20:297-305 [580252.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):201-5 [1457577.001]
  • (PMID = 20425318.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 78
  •  go-up   go-down


67. Cascarini L, Brown AE: Burkitt's lymphoma: an unusual cause of lip numbness. Dent Update; 2005 Mar;32(2):97-8, 100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma: an unusual cause of lip numbness.
  • Dental infection secondary to caries was initially diagnosed but biopsy revealed this to be a Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / complications. Hypesthesia / etiology. Lip Diseases / etiology. Mandibular Neoplasms / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dent Update. 2005 Jul-Aug;32(6):363; author reply 363 [16117360.001]
  • (PMID = 15819153.001).
  • [ISSN] 0305-5000
  • [Journal-full-title] Dental update
  • [ISO-abbreviation] Dent Update
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol
  •  go-up   go-down


68. Kaspers GJ, Wijnands JJ, Hartmann R, Huismans L, Loonen AH, Stackelberg A, Henze G, Pieters R, Hählen K, Van Wering ER, Veerman AJ: Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. Eur J Cancer; 2005 Jun;41(9):1300-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
  • At relapse, T-cell acute lymphoblastic leukaemia (ALL) has a worse patient outcome than B-cell precursor (BCP-) ALL.
  • To investigate this further, we compared in vitro cellular drug resistance profiles of T-cell and BCP-ALL samples obtained at relapse.
  • We investigated 237 paediatric relapsed ALL cases, including 151 samples taken at first relapse, of which 30 were T-cell ALL.
  • Similar results were found for first relapsed ALL samples and for the total group: T-cell ALL samples were more resistant to 4-HOO-ifosfamide (1.4-fold, P = 0.019) and cisplatin (3.7-fold, P = 0.005).
  • These results do not explain the relatively poor prognosis of T-cell ALL at relapse, but do suggest that the more intensive use of thiopurines in relapsed T-cell ALL may be beneficial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Drug Resistance, Neoplasm / immunology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Cell Line, Tumor / immunology. Child. Drug Screening Assays, Antitumor. Humans. Immunophenotyping. Lethal Dose 50. Prognosis. Recurrence

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869873.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


69. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW: Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma; 2009 Aug;9(4):307-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
  • Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens.
  • The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years.
  • We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature.
  • We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma;.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Oncology (Williston Park). 2008 Nov 30;22(13):1508-17 [19133605.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2232-3 [12805320.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Br J Haematol. 1989 Mar;71(3):371-6 [2930722.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):201-5 [1457577.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):118-47 [17335683.001]
  • [Cites] Cancer Invest. 2007 Mar;25(2):87-93 [17453819.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5316-9 [18854560.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • (PMID = 19717381.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32 HL007152-31; United States / NCI NIH HHS / CA / CA031946-27; United States / NHLBI NIH HHS / HL / HL007152-33; United States / NCI NIH HHS / CA / U10 CA031946; United States / NHLBI NIH HHS / HL / HL007152-32; United States / NCI NIH HHS / CA / U10 CA031946-28; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NCI NIH HHS / CA / CA031946-28; United States / NHLBI NIH HHS / HL / HL007152-31; United States / NHLBI NIH HHS / HL / T32 HL007152-33; United States / NHLBI NIH HHS / HL / HL007152; United States / NHLBI NIH HHS / HL / T32 HL007152-32; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA031946-27
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS207721; NLM/ PMC2909640
  •  go-up   go-down


70. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L: Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia; 2006 Mar;8(3):223-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / chemistry. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cytokines / blood. Cytokines / pharmacology. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Leukemic / drug effects. HLA-G Antigens. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / classification. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Retrospective Studies. Solubility. Tumor Escape

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jun 15;164(12):6100-4 [10843658.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):379-85 [14708718.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):280-2 [11091213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1102-7 [11137213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1138-49 [11137219.001]
  • [Cites] Hum Immunol. 2000 Dec;61(12):1347-51 [11163092.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6133-9 [11087747.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):369-76 [11466692.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12150-5 [11572934.001]
  • [Cites] Nephrologie. 2003;24(8):451-6 [14737978.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9145-9 [3480534.001]
  • [Cites] Science. 1990 Apr 13;248(4952):220-3 [2326636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3947-51 [1570318.001]
  • [Cites] Cell Immunol. 1994 May;155(2):312-22 [8181068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4209-13 [8183892.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5516-24 [7989753.001]
  • [Cites] Tissue Antigens. 1996 Nov;48(5):609-14 [8988550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5249-54 [9144223.001]
  • [Cites] J Exp Med. 1997 Jul 21;186(2):289-98 [9221758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11520-5 [9326642.001]
  • [Cites] Eur J Immunol. 1997 Dec;27(12):3380-8 [9464826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1980-90 [9645380.001]
  • [Cites] Hum Immunol. 1998 Aug;59(8):524-8 [9712358.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):277-83 [9933109.001]
  • [Cites] Tissue Antigens. 1999 Jan;53(1):14-22 [10082427.001]
  • [Cites] Int Immunol. 1999 May;11(5):803-11 [10330285.001]
  • [Cites] Am J Reprod Immunol. 1999 Jul;42(1):30-6 [10429764.001]
  • [Cites] J Reprod Immunol. 1999 Jul;43(2):105-9 [10479047.001]
  • [Cites] Autoimmun Rev. 2005 Nov;4(8):503-9 [16214086.001]
  • [Cites] Hum Immunol. 2005 Aug;66(8):853-63 [16216668.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4772-80 [11971028.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3576-86 [12516543.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1191-6 [12552087.001]
  • [Cites] Eur J Immunol. 2003 Jan;33(1):125-34 [12594841.001]
  • [Cites] Leuk Res. 2003 Jul;27(7):643-8 [12681364.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):752-61 [12878353.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):802-10 [12878359.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1017-24 [14602230.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1093-101 [14602240.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):606-11 [14697234.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):343-51 [14708714.001]
  • [Cites] Ann Neurol. 2000 Oct;48(4):679-84 [11026456.001]
  • (PMID = 16611416.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC1578523
  •  go-up   go-down


71. Kojima M, Tsukamoto N, Yokohama A, Suzuki Y, Shimizu K, Nishikawa M, Murayama K, Miyanaga T, Isoda A, Shimizu K, Itoh H, Masawa N, Yoshida K, Inagaki H: B-cell lymphoma associated with Sjögren's syndrome among Japanese patients: a clinicopathologic and immunohistochemical study of 15 cases. J Clin Exp Hematop; 2009 Nov;49(2):89-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoma associated with Sjögren's syndrome among Japanese patients: a clinicopathologic and immunohistochemical study of 15 cases.
  • To clarify the clinicopathological findings of B-cell lymphoma associated with Sjögren's syndrome (SJS) among Japanese Patients, 15 individuals with this disease were studied.
  • Histologically, six cases were marginal zone B-cell lymphoma (MZBL) of the mucosa-associated lymphoid tissue (MALT) type, three cases were diffuse large B-cell lymphoma (DLBCL) + MALT type lymphoma, two cases were nodal MZBL and one case each was small lymphocytic lymphoma, Burkitt's lymphoma, CD10(+) DLBCL and DLBCL + nodal MZBL.
  • Using in situ hybridization, numerous Epstein-Barr virus(+) tumor cells were detected only in the case of Burkitt lymphoma.
  • B-cell lymphoma associated with SJS also frequently affected extranodal organs in patients from Japan as well as from patients in Western countries.
  • The majority of B-cell lymphomas in patients with SJS also appear to be low-grade MZBLs or high-grade lymphomas probably derived from MZBL both in Western countries and in Japan.
  • [MeSH-major] Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Sjogren's Syndrome / metabolism. Sjogren's Syndrome / pathology
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Female. Humans. Immunohistochemistry / methods. Japan. Male. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907113.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, Hempstead B, Leonard JP, Chadburn A, Rafii S: Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Oct 1;12(19):5622-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma.
  • Here, we investigated whether stromal incorporation of CD68(+) hemangiogenic cells and alpha-smooth muscle actin(+) (alpha-SMA(+)) stromal cells correlates with neoangiogenesis and progression in human non-Hodgkin's lymphoma subtypes.
  • EXPERIMENTAL DESIGN: Spatial localizations of vascular and stromal cells expressing CD34, VEGFR-1, alpha-SMA, and CD68 were examined by immunohistochemistry in 42 cases of non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and compared with benign follicular hyperplasia.
  • In contrast, there was a diffuse increase in alpha-SMA incorporation throughout the stromal compartment of indolent subtype of CLL/SLL compared with the scant perivascular pattern in aggressive subtypes.
  • Overall, there was no correlation between CD34(+) microvessel density and lymphoma histologic subtype.
  • CONCLUSIONS: Heightened stromal hemangiogenesis as marked by infiltration of proangiogenic VEGFR-1(+)CD68(+)VEGF-A(+) cells and their paracrine cross-talk with neovasculature appears to be a distinct feature of aggressive lymphoma, providing novel targets for antiangiogenic therapy, whereas alpha-SMA(+) stromal vascular network may be differentially targeted in CLL/SLL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Neovascularization, Pathologic / pathology. Stromal Cells / pathology
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Microcirculation. Middle Aged. Muscle, Smooth / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020964.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL 075234; United States / NHLBI NIH HHS / HL / HL 59312; United States / NHLBI NIH HHS / HL / HL 67839; United States / NCRR NIH HHS / RR / K23 RR 016814
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


73. Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P: Lymphoma--emerging realities in sub-Saharan Africa. Transfus Apher Sci; 2010 Apr;42(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--emerging realities in sub-Saharan Africa.
  • Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the lymphoma reclassification project.
  • Median age was 55.2 years 61% were males, 10% had Hodgkin lymphoma and, overall, constitutional symptoms were present in 20%.
  • Median survival in hairy cell leukaemia (n=14), chronic lymphocytic leukaemia-small lymphocytic lymphoma (n=103), Hodgkin (n=41) and follicular lymphoma (n=59) was not reached at the time of analysis and exceeded 36 months.
  • This was followed by 32 months for those with mantle cell (n=7), splenic (n=2) and extranodal marginal cell (n=11), 24 months for T-cell lymphomas (n=24), 20 months for diffuse large B-cell variants (n=88) but only 12 months for the aggressive tumours exemplified by Burkitt (n=7) and lymphoblastic subtypes (n=6).
  • The remaining 36 patients had to be excluded because numbers were too small for statistical analysis or unreliable staging.
  • Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy cell leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin lymphoma treated according to the German study group protocols (p=0.0004).
  • Corresponding figures for chronic lymphocytic leukaemia-small lymphocytic lymphoma were 82% (p=0.0006), follicular lymphoma 71% (p=0.060), peripheral T-cell lymphoma 43% (p=0.0156), diffuse large B-cell lymphoma 39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle cell, splenic and extra nodal marginal cell lymphomas 22% (p=0.2023).
  • [MeSH-major] Lymphoma
  • [MeSH-minor] Adolescent. Adult. Africa South of the Sahara / epidemiology. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ltd.
  • (PMID = 20149748.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


74. Bariakh EA, Zvonkov EE, Kremenetskaia AM, Kravchenko SK, Magomedova AU, Obukhova TN, Samoĭlova RS, Vorob'ev IA, Kaplanskaia IB, Moiseeva TN, Zybunova EE, Lorie IuIu, Chernova NG, Mar'in DS, Egorova EK, Krasil'nikova BB, Gabeeva NG, Vorob'ev AI: [Treatment of adult Berkitt-like lymphoma]. Ter Arkh; 2005;77(7):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult Berkitt-like lymphoma].
  • AIM: To compare programs of chemotherapy used in adult Berkitt-like lymphoma (ABLL); to assess efficacy and toxicity of the protocol AblL-M-04.
  • 10 patients had diffuse large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prednisone / therapeutic use. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116910.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CHOP protocol; PVDA protocol; non-Hodgkin's lymphoma protocol 8503
  •  go-up   go-down


75. Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ: Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res; 2010 May 15;70(10):3915-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.
  • Allogeneic hematopoietic stem-cell transplantation can cure some patients with high-risk B-cell malignancies, but disease relapse following transplantation remains a significant problem.
  • One approach that could be used to augment the donor T-cell-mediated antitumor effect is the infusion of allogeneic donor-derived T cells expressing a chimeric antibody receptor (CAR) specific to the B-cell antigen CD19.
  • However, the use of such cells might result in toxicity in the form of graft-versus-host disease mediated by CD19-specific (CD19-CAR) T cells possessing alloreactive endogenous T-cell receptors.
  • Importantly, T-cell effector functions including CAR-dependent proliferation and specific target cytolysis and cytokine production were retained after alloanergization.
  • Immunotherapy with such cells could potentially reduce disease relapse after allogeneic transplantation without increasing toxicity, thereby improving the outcome of patients undergoing allogeneic transplantation for high-risk B-cell malignancies.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Blood. 2002 Jun 15;99(12):4357-63 [12036862.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):825-33 [17299405.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] Nat Med. 2003 Mar;9(3):279-86 [12579196.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2292-9 [12763937.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1375-7 [14585640.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1158-65 [14525783.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Transplantation. 2004 Sep 27;78(6):815-24 [15385799.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2403-9 [15231569.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2919-25 [15242869.001]
  • [Cites] J Immunol. 1983 Jul;131(1):244-50 [6408173.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Transplantation. 1990 Jul;50(1):1-7 [2142343.001]
  • [Cites] J Exp Med. 1993 Jan 1;177(1):165-73 [7678111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4 [8421711.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6586-90 [7688125.001]
  • [Cites] J Immunol. 1996 May 15;156(10):3587-90 [8621891.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4887-93 [8639863.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2620-30 [17507664.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):294-305 [18060041.001]
  • [Cites] Mol Ther. 2008 Mar;16(3):580-9 [18227839.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4392-402 [17878399.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2961-71 [18413766.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):16-22 [18721776.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1515-6 [18725873.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2232-41 [18617635.001]
  • [Cites] Transplantation. 2008 Sep 27;86(6):854-64 [18813111.001]
  • [Cites] Nat Med. 2008 Nov;14(11):1264-70 [18978797.001]
  • [Cites] Mol Ther. 2009 Aug;17(8):1453-64 [19384291.001]
  • [Cites] Gene Ther. 2009 Aug;16(8):1042-9 [19494842.001]
  • [Cites] N Engl J Med. 1999 Jun 3;340(22):1704-14 [10352162.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3429-36 [15284108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17312-5 [15574496.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1622-31 [15507526.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 May;11(5):362-70 [15846290.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):7046-52 [16272366.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2643-52 [16352804.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):e20-2 [16648493.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1889-92 [17041638.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15 [17062687.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10995-1004 [17108138.001]
  • [Cites] Nat Biotechnol. 2002 Dec;20(12):1221-7 [12415288.001]
  • (PMID = 20424114.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA120956-01A1; United States / NCI NIH HHS / CA / R01 CA141303; United States / NCI NIH HHS / CA / R01 CA124782-01A1; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA124782; United States / NCI NIH HHS / CA / CA124782-03S2; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / R21 CA116127-01A1; United States / NCI NIH HHS / CA / R21S CA116127; United States / NCI NIH HHS / CA / P01 CA100265; United States / NCI NIH HHS / CA / 5P30CA016672-32; United States / NCI NIH HHS / CA / R01S CA120956; United States / NCI NIH HHS / CA / R01S CA124782; United States / NCI NIH HHS / CA / CA116127-01A1; United States / NCI NIH HHS / CA / R21S CA129390; United States / NCI NIH HHS / CA / R21S CA137645; United States / NCI NIH HHS / CA / R21 CA129390; United States / NCI NIH HHS / CA / U19 CA100265; United States / NCI NIH HHS / CA / R01 CA124782-03S2; United States / NCI NIH HHS / CA / R21 CA116127; United States / NCI NIH HHS / CA / CA124782-01A1; United States / NCI NIH HHS / CA / R33 CA116127; United States / NCI NIH HHS / CA / R01 CA120956-01A1; United States / NCI NIH HHS / CA / R21 CA137645; United States / NCI NIH HHS / CA / R01 CA120956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19
  • [Other-IDs] NLM/ NIHMS188106; NLM/ PMC2873153
  •  go-up   go-down


76. Tagawa H: [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis]. Gan To Kagaku Ryoho; 2007 Jul;34(7):975-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We herein report the characteristic genomic alterations of malignant lymphomas including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and adult T cell lymphoma/leukemia (ATLL).
  • For instance, we revealed that activated B-cell-like DLBCL is characterized by a gain of chromosome 3, 18q and loss of 9 p21, whereas the germinal center B-cell-like DLBCL is characterized by a gain of 2p15, 7q, and 12q.
  • Comparison of genome profiles between acute type and lymphoma types of adult T cell lymphoma also demonstrated that acute and lymphoma types are genomically distinct subtypes, and thus may develop tumors via distinct genetic pathways.
  • Furthermore,we developed a computer algorithm to classify lymphoma diseases or subtypes on the basis of copy number gains and losses.
  • [MeSH-major] Gene Dosage. Gene Expression Profiling. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Follicular / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Genome, Human. Humans. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637530.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


77. Degeorges S, Mesnil A, Marion-Audibert AM, Bouafia-Sauvy F, Berger F, Bancel B, Barnoud R, Rode A, Péré-Vergé D, Souquet JC: [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient]. Gastroenterol Clin Biol; 2007 Apr;31(4):442-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient].
  • [Transliterated title] Manifestations anorectales, en rapport avec un lymphome de Burkitt associé au virus Epstein Barr, chez une malade immunocompétente.
  • Final diagnosis confirmed by biopsy performed during rectosigmoidoscopy was an Epstein-Barr Virus-Associated Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Female. Humans. Immunocompetence. Magnetic Resonance Imaging. Rectum / pathology. Sigmoidoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483786.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


78. Kyoung Jung H, Kim EK, Yun M, Jung Kim M, Young Kwak J: Bilateral breasts involvement in Burkitt's lymphoma detected only by FDG-PET. Clin Imaging; 2006 Jan-Feb;30(1):57-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral breasts involvement in Burkitt's lymphoma detected only by FDG-PET.
  • Burkitt's lymphoma can occur from elsewhere in the body, but involvement of the breasts is very rare.
  • However, we experienced the involvement of bilateral whole breasts in a patient with underlying Burkitt's lymphoma, which showed negative mammographic and ultrasonographic findings, but bilateral hot uptakes of the breast in FDG-PET scan.
  • [MeSH-major] Breast Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Positron-Emission Tomography
  • [MeSH-minor] Adult. Fatal Outcome. Female. Fluorodeoxyglucose F18. Humans. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377487.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


79. Heerema NA, Bernheim A, Lim MS, Look AT, Pasqualucci L, Raetz E, Sanger WG, Cairo MS: State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY. Pediatr Blood Cancer; 2005 Oct 15;45(5):616-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY.
  • BACKGROUND: A significant number of studies describe the cytogenetics and molecular genetics of adult non-Hodgkin lymphoma (NHL); however, similar knowledge is lacking regarding pediatric NHL.
  • METHODS: A workshop to discuss the "State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays" in pediatric NHL was held in conjunction with the First International Symposium on Childhood and Adolescent Non-Hodgkin Lymphoma on April 9, 2003 in New York City.
  • RESULTS: Cytogenetic characteristics of pediatric NHL include 14q11.2 rearrangements in T-cell lymphoblastic leukemia/lymphomas (LBL), ALK rearrangements in anaplastic large cell lymphomas (ALCL), and CMYC translocations in both Burkitt and Burkitt-like lymphomas (BL/BLL).
  • Pediatric diffuse large B-cell lymphoma (DLBCL) is cytogenetically different from DLBCL in adults, suggesting a different disease in children.
  • Microarray studies demonstrate three types of T-cell leukemia, the leukemic counterpart of LBL, that block T-cell differentiation at different stages of T-cell development, corresponding to LYL, TAL1, and HOX-expressing leukemias.
  • ALCL cell lines have a unique expression profile compared to normal T-cells.
  • Germinal centers of BL have CMYC expression signatures, indicating that CMYC expression is ectopic and does not reflect the physiology of the normal cell counterpart.
  • CONCLUSIONS: Additional cytogenetic, molecular and microarray investigations of NHL in children are vital to better understand these diseases, their etiology, and differences from adult NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Basic Helix-Loop-Helix Transcription Factors. Burkitt Lymphoma / genetics. Child. Cytogenetic Analysis. DNA-Binding Proteins / genetics. Gene Rearrangement. Homeodomain Proteins / genetics. Humans. Intracellular Signaling Peptides and Proteins. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Microarray Analysis. Molecular Biology. Neoplasm Proteins / genetics. Oncogene Proteins / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127683.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13-CA10195-01
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LYL1 protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / STIL protein, human; 0 / TLX3 protein, human
  •  go-up   go-down


80. Burmeister T, Schwartz S, Horst HA, Rieder H, Gökbuget N, Hoelzer D, Thiel E: Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia; 2005 Aug;19(8):1391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.
  • Chromosomal translocations involving the MYC oncogene are a hallmark of Burkitt lymphoma but they are only found in a varying frequency in mature Burkitt-type acute lymphoblastic leukemia (B-ALL).
  • We have investigated samples of 56 sporadic Burkitt leukemia/lymphoma patients for the translocations t(8;14)(q24;q32), t(2;8)(p11;q24) and t(8;22)(q24;q11).
  • [MeSH-major] Burkitt Lymphoma / genetics. Genetic Heterogeneity. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Cytogenetic Analysis. Female. Genes, myc. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Polymerase Chain Reaction. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Leukemia (2005) 19, 1391-1398.
  • (PMID = 15973450.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


81. Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC: Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr; 2010 May 1;54(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.
  • To aid in case classification and identify key pathogenetic events in ARL, we analyzed gene expression data and somatic DNA copy number changes by high-resolution array comparative genomic hybridization in tumors from 20 B-cell derived ARL (B-ARL) patients.
  • Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.
  • [MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216076.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Mossafa H, Damotte D, Jenabian A, Delarue R, Vincenneau A, Amouroux I, Jeandel R, Khoury E, Martelli JM, Samson T, Tapia S, Flandrin G, Troussard X: Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma; 2006 Sep;47(9):1885-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
  • Out of 344 patients with newly diagnosed non-Hodgkin's lymphoma (NHL), this study identified 16 patients presenting Burkitt-like cells (BLCs) after cytological and/or histological review.
  • The BLCs were present whatever the lymphoma sub-type: follicular lymphoma (FL) was diagnosed in six out of 16 patients, mantle cell lymphoma (MCL) in four out of 16 patients, marginal zone lymphoma (MZL) in two out of 16 patients and diffuse large B-cell lymphomas (DLBCL) in three out of 16 patients.
  • One additional patient presented a T-cell lymphoma.
  • These data could suggest a sub-group of NHL patients (15 B-NHL, 1 T-NHL) have been identified with a poor prognosis characterized by the association of Burkitt-like cells and c-MYC amplification without t(8;14)(q24;q32) or its variants.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Amplification. Lymphoma, T-Cell / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human / genetics. Cytogenetic Analysis. Female. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Male. Middle Aged. Prognosis. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065002.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


83. Panayotakopoulos GD, Day S, Peters BS, Kulasegaram R: Severe osteoporosis and multiple fractures in an AIDS patient treated with short-term steroids for lymphoma: a need for guidelines. Int J STD AIDS; 2006 Aug;17(8):567-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe osteoporosis and multiple fractures in an AIDS patient treated with short-term steroids for lymphoma: a need for guidelines.
  • An HIV-1 infected patient on dual protease inhibitor treatment developed spontaneous vertebral fractures and avascular necrosis of the femoral bone after receiving combined chemotherapy for Burkitt's lymphoma including short-term prednisolone.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / virology. Fractures, Compression / etiology. HIV-1. Osteoporosis / etiology. Prednisolone / adverse effects
  • [MeSH-minor] Adult. Anti-Retroviral Agents / therapeutic use. HIV Protease Inhibitors / therapeutic use. Humans. Male


84. Takenokuchi M, Saigo K, Nakamachi Y, Kawano S, Hashimoto M, Fujioka T, Koizumi T, Tatsumi E, Kumagai S: Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). Acta Haematol; 2006;116(1):30-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
  • Recent studies reported that PPARgamma ligands inhibit cell proliferation and induce apoptosis in both normal and malignant B-lineage cells.
  • We investigated the expression of PPARgamma and the effects of PPARgamma ligands on UTree-O2, Bay91 and 380, three B-cell acute lymphoblastic leukemia (B-ALL) cell lines with t(14;18), which show a poor prognosis, accompanying c-myc abnormality.
  • Western blot analysis identified expression of PPARgamma protein and real-time PCR that of PPARgamma mRNA on the three cell lines.
  • Troglitazone (TGZ), a synthetic PPARgamma ligand, inhibited cell growth in these cell lines in a dose-dependent manner, which was associated with G(1) cell cycle arrest and apoptosis.
  • TGZ was found to dose-dependently downregulate the expression of c-myc mRNA and c-myc protein in the three cell lines.
  • These results suggest that TGZ inhibits cell growth via induction of G(1) cell cycle arrest and apoptosis in these cell lines and that TGZ-induced apoptosis, at least in part, may be related to the downregulation of c-myc expression.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Burkitt Lymphoma / metabolism. Chromans / pharmacology. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. G1 Phase / drug effects. PPAR gamma / biosynthesis. Thiazolidinediones / pharmacology. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Dose-Response Relationship, Drug. Down-Regulation / drug effects. Female. Gene Expression Regulation, Leukemic / drug effects. Humans. Ligands. Male. Prognosis. Proto-Oncogene Proteins c-myc / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction


85. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F, Agura E, Chauncey T, Maziarz RT, Maris M, Shizuru J, Bruno B, Bredeson C, Lange T, Yeager A, Sandmaier BM, Storb RF, Maloney DG: Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol; 2008 Nov;143(3):395-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.
  • Patients with relapsed diffuse large B-cell lymphoma (DLBCL) who have failed or are ineligible for autologous haematopoietic cell transplantation (HCT) have a poor prognosis.
  • We examined the outcomes of non-myeloablative allogeneic HCT in this setting.
  • Thirty-one patients with DLBCL and one patient with Burkitt lymphoma received allogeneic HCT following 2 Gy total body irradiation with or without fludarabine.
  • Three-year cumulative incidences of relapse and non-relapse mortality were 41% and 25% respectively.
  • Non-myeloablative allogeneic HCT can produce long-term disease-free survival in patients with chemosensitive relapsed DLBCL who have failed or are ineligible for autologous HCT.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25 [18342784.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4022-31 [12351600.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2021-30 [12791654.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3447-54 [12855572.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2419-23 [15197204.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1621-9 [2809678.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):638-47 [2313333.001]
  • [Cites] Semin Hematol. 1991 Jul;28(3):250-9 [1887253.001]
  • [Cites] Blood. 1992 Oct 15;80(8):2142-8 [1356515.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1690-5 [1403052.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1050-5 [8049425.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):588-95 [7884420.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(2):121-7 [9116608.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):859-63 [9404927.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3515-20 [9808542.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):154-61 [10520036.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Apr;11(4):272-9 [15812392.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Aug;11(8):593-9 [16041309.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):223-30 [16197454.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11 [16785059.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(3):272-9 [10871152.001]
  • (PMID = 18759762.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / P01 CA018029-33; United States / NHLBI NIH HHS / HL / R00 HL088021; United States / NHLBI NIH HHS / HL / HL088021-02; United States / NCI NIH HHS / CA / CA15704; United States / NHLBI NIH HHS / HL / K99 HL088021-02; United States / NCI NIH HHS / CA / P30 CA015704-34; United States / NCI NIH HHS / CA / P01 CA078902; United States / NHLBI NIH HHS / HL / K99 HL088021; None / None / / P01 CA018029-33; United States / NCI NIH HHS / CA / P01 CA078902-10; United States / NHLBI NIH HHS / HL / HL088021
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ NIHMS91914; NLM/ PMC2654416
  •  go-up   go-down


86. Wanschitz J, Dichtl W, Budka H, Löscher WN, Boesch S: Acute motor and sensory axonal neuropathy in Burkitt-like lymphoma. Muscle Nerve; 2006 Oct;34(4):494-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute motor and sensory axonal neuropathy in Burkitt-like lymphoma.
  • Immune-mediated neuropathies associated with non-Hodgkin's lymphoma are rare and can be difficult to delineate from neuropathies of other etiologies.
  • We report the clinical and pathological findings of a 36-year-old patient with fulminant quadriplegic neuropathy, left facial nerve palsy, and Burkitt-like lymphoma.
  • We hypothesize that immune mechanisms triggered by the lymphoma initiated damage to the peripheral nervous system and enhanced its vulnerability to the toxic effects of vincristine.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Burkitt Lymphoma / drug therapy. Peripheral Nervous System Diseases / chemically induced. Vincristine / adverse effects
  • [MeSH-minor] Acute Disease. Adult. Axons / drug effects. Axons / pathology. Diagnosis, Differential. Female. Guillain-Barre Syndrome / chemically induced. Guillain-Barre Syndrome / diagnosis. Humans. Quadriplegia / chemically induced

  • Genetic Alliance. consumer health - Motor neuropathy.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671108.001).
  • [ISSN] 0148-639X
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


87. Mwakigonja AR, Kaaya EE, Mgaya EM: Malignant lymphomas (ML) and HIV infection in Tanzania. J Exp Clin Cancer Res; 2008;27:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sections of 176 archival formalin-fixed paraffin-embedded biopsies of ML patients at Muhimbili National Hospital (MNH)/Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania from 1996-2001 were stained for hematoxylin and eosin and selected (70) cases for expression of pan-leucocytic (CD45), B-cell (CD20), T-cell (CD3), Hodgkin/RS cell (CD30), histiocyte (CD68) and proliferation (Ki-67) antigen markers.
  • RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).
  • Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.
  • Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology


88. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ, Lacruz J, Valencia E, Santos J, Rodríguez-Arrondo F, Pintado V, Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas: Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr; 2007 Feb 1;44(2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
  • OBJECTIVES: To assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART).
  • Histologic subtypes were diffuse large B-cell lymphoma (DLCL; n = 153 [72.9%]), Burkitt and atypical Burkitt/Burkitt-like lymphoma (BL; n = 40 [19.0%]), T-cell lymphoma (TC; n = 8 [3.8%]), and miscellaneous (n = 9 [4.3%]).
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Remission Induction. Statistics as Topic. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117144.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


89. Liu J, Hughes-Oliver JM, Menius JA Jr: Domain-enhanced analysis of microarray data using GO annotations. Bioinformatics; 2007 May 15;23(10):1225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Burkitt Lymphoma / genetics. Computational Biology. Leukemia-Lymphoma, Adult T-Cell / genetics. Oligonucleotide Array Sequence Analysis. Software

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379692.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Grant] United States / NHGRI NIH HHS / HG / 1 P20 HG003900-01
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


90. Tarrand JJ, Keating MJ, Tsimberidou AM, O'Brien S, LaSala RP, Han XY, Bueso-Ramos CE: Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer; 2010 Feb 15;116(4):880-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a later cohort of patients after hematopoietic stem cell transplantation, 4 of 7 patients with Hodgkin lymphoma or Burkitt lymphoma had EBV LMP1 detected.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / virology. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / metabolism. Bone Marrow / pathology. Bone Marrow / virology. Cell Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Messenger / metabolism. RNA, Viral / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Epstein Barr Virus, Chronic.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052729.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


91. Khurshed A, Ahmed R, Bhurgri Y: Primary gastrointestinal malignancies in childhood and adolescence--an Asian perspective. Asian Pac J Cancer Prev; 2007 Oct-Dec;8(4):613-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoma comprised 47 cases (78.3%; 32 boys and 15 girls.) and lymphoma 13 cases (21.7%; 12 boys and 1 girl).
  • Lymphoid malignancies were diffuse large B-cell lymphoma (30.8%), Burkitt lymphoma (46.1%) and Burkitt-like lymphoma (23.1%).
  • CONCLUSION: This study has identified a substantial number of GI malignancies in the <or=19 year Pakistani population, involvement of esophagus, male predominance, preponderance of carcinoma versus lymphoma and a high signet ring cell and mucinous colo-rectal carcinoma.
  • It has identified Baluchistan as a high risk region for esophageal cancer and diffuse large B-cell lymphoma and NWFP for Burkitt and Burkitt-like lymphoma.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Infant. Infant, Newborn. Male. Pakistan / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260739.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


92. Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, De Marco F, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omedè P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M: Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia; 2007 Apr;21(4):697-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients.
  • Some evidences suggest that telomere restriction fragment length (TRF-L) is an effective indicator of histopathogenesis in B-cell tumors.
  • As histopathogenesis is relevant for B-cell chronic lymphocytic leukemia (B-CLL) prognosis, TRF-L was assessed by Southern blot in 201 patients and compared to variable immunoglobulin heave chain gene mutational status (VH-MS) and to other known prognostic features.
  • [MeSH-major] Burkitt Lymphoma / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Telomere / ultrastructure
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Allelic Imbalance. Disease-Free Survival. Humans. Immunoglobulin Variable Region. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis


93. Shim GJ, Gherman D, Kim HJ, Omoto Y, Iwase H, Bouton D, Kis LL, Andersson CT, Warner M, Gustafsson JA: Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol; 2006 Feb;208(3):408-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, in different human lymphoma cell lines including Hodgkin lymphoma, Burkitt lymphoma, and multiple myeloma, ERbeta is abundant while ERalpha is not detectable.
  • [MeSH-minor] Adult. Blotting, Western / methods. Breast Neoplasms / immunology. Burkitt Lymphoma / chemistry. Cell Line. Cell Line, Tumor. Child, Preschool. Estrogen Receptor alpha / analysis. Estrogen Receptor beta / analysis. Female. Hodgkin Disease / metabolism. Humans. Leukocytes / chemistry. Leukocytes, Mononuclear / chemistry. Male. Palatine Tonsil / chemistry. Spleen / chemistry

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294372.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Receptors, Estrogen
  •  go-up   go-down


94. Wu JY, Huang XJ: [Investigation of plasmacytoid dendritic cell reconstitution and its relationship with cGVHD and relapse after haploidentical hematopoietic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of plasmacytoid dendritic cell reconstitution and its relationship with cGVHD and relapse after haploidentical hematopoietic stem cell transplantation].
  • To investigate the characteristics and significance of reconstitution of peripheral blood plasmacytoid dendritic cell (PDC) precursors after allogeneic human leukocyte antigen mismatched/haploidentical hematopoietic stem cell transplantation, and its relationship with chronic graft versus host disease (cGVHD) and relapse, 19 patients with leukemia were enrolled for this study.
  • Peripheral blood dendritic cell (DC) subsets of patients and healthy controls were detected by flow cytometry, and the correlations between reconstitution of DC and cGVHD, relapse were analyzed.
  • The results showed that compared with healthy subjects, patients with leukemia had a significantly decreased proportion and absolute number of myeloid dendritic cell (MDC), MDC1, DC and the ratio of MDC/PDC (P<0.05).
  • It is concluded that compared with healthy subjects, de novo leukemia patients have a significantly decreased proportion and absolute number of DC and the ratio of MDC/PDC before haploidentical hematopoietic stem cell transplantation; while ratio of MDC/PDC can be normalized with relative rapidity, the proportions of all DC subsets reached to normal levels on the whole at 9 months after transplantation, and also recovery level of DCs is correlated with occurrence of cGVHD and relapse.


95. Meleshko AN, Belevtsev MV, Savitskaja TV, Potapnev MP: The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression. Leuk Res; 2006 Jul;30(7):795-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression.
  • Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangement is conventionally used for assessment of lymphoid malignant cells.
  • It was shown that clonal cross-lineage TCR rearrangements were associated with more immature immunophenotype (CD34+, CD117+, CyIgM-) of leukemic cells from patients' bone marrow (BM) samples as compared to cell samples without cross-lineage TCR rearrangements.
  • [MeSH-major] Burkitt Lymphoma / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Immunophenotyping. Infant. Male. Polymerase Chain Reaction / methods. Recurrence. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386788.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / TEL-AML1 fusion protein; 146150-85-8 / E2A-Pbx1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


96. Beesley AH, Cummings AJ, Freitas JR, Hoffmann K, Firth MJ, Ford J, de Klerk NH, Kees UR: The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol; 2005 Nov;131(4):447-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Relapse specimens overexpressed genes that are involved with cell growth and proliferation, in keeping with their aggressive phenotype.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Antigens, CD147 / genetics. Antigens, CD147 / metabolism. Cell Division / genetics. Child. Child, Preschool. Drug Resistance, Neoplasm / genetics. Gene Expression Profiling. Humans. Infant. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Prognosis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Treatment Failure. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 Oct;135(2):274-5 [16965384.001]
  • (PMID = 16281934.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Neoplasm Proteins; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


97. Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P, Kalinova M, Handgretinger R, Trka J, Müller I: WT1 protein expression in childhood acute leukemia. Am J Hematol; 2008 May;83(5):382-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the relation between expression of WT1 transcripts and of the encoded protein, we examined leukemic cell lines and primary childhood leukemia samples using both real-time quantitative PCR (RQ-PCR) and flow cytometry.
  • WT1 protein was highly expressed in the leukemic cell lines K562, HL-60, PLB 985, KG-1a and CEM.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Neoplasm Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. WT1 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Blood Cells / metabolism. Bone Marrow Cells / metabolism. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / metabolism. Child. Child, Preschool. Female. Flow Cytometry. Genes, Wilms Tumor. Humans. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Male. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18161786.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins
  •  go-up   go-down


98. Okebe JU, Lasserson TJ, Meremikwu MM, Richards S: Therapeutic interventions for Burkitt's lymphoma in children. Cochrane Database Syst Rev; 2006;(4):CD005198
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic interventions for Burkitt's lymphoma in children.
  • BACKGROUND: Burkitt's lymphoma (BL) is a small non-cleaved cell lymphoma which commonly presents as jaw swellings.
  • AUTHORS' CONCLUSIONS: This review does not currently provide any strong evidence on the relative effectiveness of interventions to treat Burkitt's lymphoma.
  • The studies that have been conducted to date are small, underpowered and prone to both systematic and random error.
  • [MeSH-major] Burkitt Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Humans. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cochrane Database Syst Rev. 2011;(7):CD005198 [21735399.001]
  • (PMID = 17054245.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


99. Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, Bierman PJ, Bociek RG, Armitage JO: Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park); 2008 Nov 30;22(13):1508-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma: advances in diagnosis and treatment.
  • Burkitt lymphoma is a unique B-cell malignancy with a high proliferation rate and characteristic genetic changes involving the c-myc oncogene.
  • Burkitt lymphoma is common in children but also occurs in adults, where distinction from diffuse large B-cell lymphoma may pose a problem.
  • The development of brief, very intensive chemotherapy regimens has led to a very high cure rate in children with Burkitt lymphoma.
  • Burkitt lymphoma in adults cannot be treated effectively with the common regimens used for diffuse large B-cell lymphoma such as CHOP-R (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone, rituximab).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Clinical Trials, Phase II as Topic. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Genes, myc. Humans. Ifosfamide / administration & dosage. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Practice Guidelines as Topic. Prednisone / administration & dosage. Prognosis. Rituximab. Stem Cell Transplantation / methods. Survival Analysis. Teniposide / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2008 Nov 30;22(13):1518-9 [19227573.001]
  • [CommentOn] Oncology (Williston Park). 2008 Nov 30;22(13):1519, 1522-3 [19227574.001]
  • (PMID = 19133605.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; Q573I9DVLP / Leucovorin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 89
  •  go-up   go-down


100. Song X, Gong S, Yang J, Wang J: Clinical and molecular cytogenetic characteristics of dic(9;20) in adult acute lymphoblastic leukemia: a case report of three patients. Ann Hematol; 2007 May;86(5):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and molecular cytogenetic characteristics of dic(9;20) in adult acute lymphoblastic leukemia: a case report of three patients.
  • In this study, we report three adult patients with acute lymphoblastic leukemia (ALL) with dic(9;20) anomaly.
  • All three patients were diagnosed as cluster of differentiation 10 (CD10) positive B cell ALL, achieved complete remission after induction chemotherapy, and died of leukemia relapse within 1 year after diagnosis.
  • The prognostic significance of dic(9;20) in adult patients with ALL remains to be determined.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 20. Chromosomes, Human, Pair 9. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245591.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement